%PDF-1.3 % 3 0 obj <>>>/BBox[0 0 612 792]/Length 53>>stream xs w3T0WI2P0T5TR Ɩf !\!Y\ !p o endstream endobj 6 0 obj <>>>/BBox[0 0 612 792]/Length 53>>stream xs w3T0WI2P0T5TR Ɩf !\!Y\ !p o endstream endobj 1 0 obj <>>>/BBox[0 0 612 792]/Length 53>>stream xs w3T0WI2P0T5TR Ɩf !\!Y\ !p o endstream endobj 7 0 obj <>>>/BBox[0 0 612 792]/Length 53>>stream xs w3T0WI2P0T5TR Ɩf !\!Y\ !p o endstream endobj 5 0 obj <>>>/BBox[0 0 612 792]/Length 53>>stream xs w3T0WI2P0T5TR Ɩf !\!Y\ !p o endstream endobj 8 0 obj <>>>/BBox[0 0 612 792]/Length 53>>stream xs w3T0WI2P0T5TR Ɩf !\!Y\ !p o endstream endobj 4 0 obj <>>>/BBox[0 0 612 792]/Length 53>>stream xs w3T0WI2P0T5TR Ɩf !\!Y\ !p o endstream endobj 10 0 obj <>stream application/pdf POP-2018-0175-ver9-Bluml_4P 522..528 2019-11-28T19:01:24+05:30 Arbortext Advanced Print Publisher 9.0.114/W 2021-03-15T10:50:46-07:00 Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT uuid:9f6042ca-ef66-4d7c-a06f-e83c105e6a1a uuid:28191e51-c6c7-4feb-9cdd-5dd4dce6b424 endstream endobj 11 0 obj <>stream x+| endstream endobj 12 0 obj <>stream xS**T0T0BiyS& endstream endobj 13 0 obj <>stream x+| endstream endobj 14 0 obj <>stream xS**T0T0BiyJ% endstream endobj 15 0 obj <>stream x+| endstream endobj 16 0 obj <>stream xS**T0T0BiyA$ endstream endobj 17 0 obj <>stream x+| endstream endobj 18 0 obj <>stream xS**T0T0Biyn) endstream endobj 19 0 obj <>stream x+| endstream endobj 20 0 obj <>stream xS**T0T0Biy8# endstream endobj 21 0 obj <>stream x+| endstream endobj 22 0 obj <>stream xS**T0T0Biye( endstream endobj 23 0 obj <>stream x+| endstream endobj 24 0 obj <>stream xS**T0T0Biy\' endstream endobj 26 0 obj <>stream /GS1 gs BT /F4 1 Tf 9.843 0 0 9.843 69.7323 725.1588 Tm 0 0 0 rg 0 Tc 0 Tw [(AADE)-480.5(sought)-478.8(to)-480.4(test)-483.7(a)-480.3(scalable)-480.1(intervention)-482.6(model)-480.3(to)]TJ -1.0137 -1.1174 TD [(address)-389.8(the)-384.7(need)-386.9(for)-389.1(ongoing)-388(diabetes)-386.7(support)-387.8(for)-383.4(individ-)]TJ 0 -1.1116 TD [(uals)-397.2(receiving)-399.5(care)-399.5(in)-394(a)-393.9(Federally)-399.4(Qualied)-398(Health)-396(Center)]TJ T* [(\(FQHC\))-308.7(with)-305(HbA1c)]TJ /F5 1 Tf 8.8987 0 TD (>)Tj /F4 1 Tf .5529 0 TD [(8,)-304(meaning)-305.1(that)-305.3(they)-305.2(were)-307.1(above)-301.6(the)]TJ -9.4517 -1.1116 TD [(Healthcare)-426.9(Effectiveness)-423.2(Data)-416.7(and)-419.2(Information)-417.9(Set)-419.1(deni-)]TJ 0 -1.1174 TD [(tion)-569.1(of)-572.4(glycemic)-572.5(control.)]TJ 7.3823 0 0 6.5614 166.9039 674.7021 Tm (7)Tj 9.843 0 0 9.843 176.2015 670.3369 Tm [(The)-570.1(study)-569.9(was)-569.6(conducted)-572.2(to)]TJ -11.8304 -1.1116 TD [(answer)-476.1(the)-471.1(question)-470.8(of)-468.7(whether)-477.5(augmented)-469.8(diabetes)-478.9(self-)]TJ T* [(management)-761.3(support)-756.4(with)-754.3(an)-752.1(economically)-762.5(vulnerable)]TJ 0 -1.1174 TD [(population)-490.6(addresses)-485.1(unmet)-486.1(needs)-485.7(and)-488.3(reduces)-489(morbidity)]TJ 0 -1.1116 TD [(and)-338.5(premature)-337.2(mortality.)]TJ 7.3823 0 0 6.5614 159.4204 630.8786 Tm (8)Tj /F3 1 Tf 8.9663 0 0 8.9663 59.7543 603.7794 Tm (Methods)Tj /F8 1 Tf 0 -1.8336 TD [(Program)-339.5(description)]TJ /F4 1 Tf 9.843 0 0 9.843 69.7323 570.8975 Tm [(A)-837.1(randomized)-839.5(clinical)-842.2(trial)-836.4(registered)-843.9(at)-832.9(Clinc)-8(ial-)]TJ -1.0137 -1.1116 TD [(Trials.gov)-257.6(#)-248.8(NCT02160639)-251.4(was)-252.8(conducted)-249.7(at)-251.2(4)-254.5(sites.)-251.9(A)-249.6(total)]TJ 25.5097 16.7838 TD [(of)-267.1(446)-262.5(individuals)-272.8(were)-266.8(enrolled)-270.5(\(Table)-269.4(1\).)-270.5(The)-264.9(intervention)]TJ 0 -1.1174 TD [(utilized)-340(pre)-344.3(and)-338.5(post)-338.4(comparisons.)-347.1(The)-339.7(study)-339.5(was)-345(designed)]TJ 0 -1.1116 TD [(to)-417(test)-420.3(the)-419.3(efcacy)-426.9(of)-416.9(a)-417(telephonic)-423.8(diabetes)-427.1(support)-416.6(inter-)]TJ T* [(vention)-291.4(to)-284.6(increase)-295.6(patient)-292.7(engagement)-293.5(in)-284.5(self-care)-296.6(utilizing)]TJ T* [(the)-361.7(health)-360.5(care)-359.2(system)-365.8(as)-360.3(a)-359.4(means)-360.2(to)-359.4(improve)-361.5(clinical)-364.2(out-)]TJ 0 -1.1174 TD [(comes.)-294.5(The)-293.7(study)-287.7(was)-293.1(reviewed)-301.3(and)-292.4(approved)-293.3(by)-290.2(Schulman)]TJ 0 -1.1116 TD [(Institutional)-373.1(Review)-368.1(Board)-376.3(\(Blue)-370.7(Ash,)-370.3(OH\).)-365.6(Study)-374.1(partici-)]TJ T* [(pants)-334.9(provided)-332.6(written)-338.4(informed)-333.8(consent.)]TJ /F8 1 Tf 8.9663 0 0 8.9663 310.8472 620.2203 Tm [(Study)-332.3(population)]TJ /F4 1 Tf 9.843 0 0 9.843 320.8251 603.7794 Tm [(To)-262.6(be)-268.3(eligible,)-268.5(individuals)-267(needed)-269.3(to)-267.3(be)-268.3(either)-268.3(English-)-269.2(or)]TJ -1.0137 -1.1174 TD [(Spanish-speaking)-383.7(adults,)-379.9(ages)-380.9(2185)-379.9(years,)-379.7(and)-378.8(have)-381.1(a)-382.4(di-)]TJ 0 -1.1116 TD [(agnosis)-492.4(of)-491.7(type)-495.3(2)-490.7(diabetes)-496.2(mellitus.)-493(It)-491.9(was)-494.7(required)-495(that)]TJ T* [(study)-454.7(participants)-466.3(had)-453.7(not)-458.4(participated)-461.9(in)-457.3(a)-457.3(diabetes)-461.6(self-)]TJ T* [(management)-438.7(education)-434.1(\(DSME\))-435.6(program)-436.3(in)-434.3(the)-430.8(last)-437.6(year,)]TJ ET 59.754 527.244 490.167 .22675 re f 59.754 95.301 490.167 .22675 re f 190.035 508.365 81.241 .22675 re f 283.635 508.365 81.241 .22675 re f 377.235 508.365 81.241 .22675 re f 59.754 490.677 490.167 .22678 re f BT /F7 1 Tf 9.845 0 0 9.845 107.9433 532.9133 Tm (Table)Tj /F4 1 Tf 2.9944 0 TD (1.)Tj /F7 1 Tf 1.2554 0 TD [(Demographics)-332.2(and)-337.8(Baseline)-332.4(Comparison)-336.2(of)-337(Control)-331.2(and)-337.8(Intervention)-331.9(Groups)]TJ /F9 1 Tf 7.1579 -1.8427 TD [(Total)-6892.3(Control)-5501.8(Intervention)]TJ -2.6489 -1.8139 TD 4.0042 Tc [(N%N%)5.8(N%)]TJ 28.1017 0 TD 0 Tc (Chi-square)Tj /F4 1 Tf 5.7528 0 TD (t)Tj /F9 1 Tf .6162 0 TD (Test)Tj /F4 1 Tf -48.1242 -1.9003 TD [(Total)-11110.1(446)-2340.9(100)-4166.4(225)-2836.2(50.4)-3421.2(221)-2836.2(49.6)]TJ /F9 1 Tf 43.6958 0 TD 4.0331 Tc (PP)Tj /F4 1 Tf -43.6958 -1.0077 TD 0 Tc [(Completed)-336.2(Study)]TJ 2.004 -1.0135 TD [(No)-10011.2(258)-2836.2(57.8)-3421.2(136)-2836.2(60.4)-3421.2(122)-2836.2(55.2)-4544.1(0.262)]TJ T* [(Yes)-9679.1(188)-2836.2(42.2)-3922.1(89)-2835.2(39.6)-3922.1(99)-2835.2(44.8)]TJ -2.004 -1.3129 TD (Sex)Tj 2.004 -1.0135 TD [(Female)-8274.1(261)-2836.2(58.7)-3421.2(135)-2836.2(60.00)-2921.2(126)-2836.2(57.3)-4544.1(0.559)]TJ T* [(Male)-9169.1(184)-2836.2(41.3)-3922.1(90)-2835.2(40.00)-3422.1(94)-2835.2(42.7)]TJ -2.004 -1.3129 TD (Ethnicity)Tj 2.004 -1.0135 TD [(White)-8773.1(218)-2836.2(48.9)-3421.2(110)-2836.2(48.9)-3421.2(108)-2836.2(48.9)-4544.1(0.650)]TJ T* [(African)-332.8(American/Black)-1762.3(98)-2835.2(22.00)-3422.1(49)-2835.2(21.8)-3922.1(49)-2835.2(22.2)]TJ 0 -1.0077 TD [(Hispanic)-7670.1(115)-2836.2(25.8)-3922.1(58)-2835.2(25.8)-3922.1(57)-2835.2(25.8)]TJ 0 -1.0135 TD [(Native)-331.9(American)-4770.2(12)-3336.2(2.7)-4422.2(5)-3335.2(2.2)-4422.2(7)-3335.2(3.2)]TJ T* [(Other)-9952.1(2)-3335.2(0.4)-4422.2(2)-3335.2(0.9)-4422.2(0)-3335.2(0.00)]TJ T* [(Not)-332.2(Specied)-6673.9(1)-3335.2(0.2)-4422.2(1)-3335.2(0.4)-4422.2(0)-3335.2(0.00)]TJ -2.004 -1.3129 TD [(Preferred)-340.5(language)]TJ 2.004 -1.0135 TD [(English)-8168.1(286)-2836.2(82.7)-3421.2(141)-2836.2(82)-4171.2(145)-2836.2(83.3)-4544.1(0.739)]TJ T* [(Spanish)-8565.1(60)-2835.2(17.3)-3922.1(31)-2835.2(18)-4672.2(29)-2835.2(16.7)]TJ -2.004 -1.313 TD [(Smoking)-336.3(Status)]TJ 2.004 -1.0135 TD [(Nonsmoker)-7066.1(44)-2835.2(31.2)-3922.1(23)-2835.2(33.8)-3922.1(21)-2835.2(28.8)-4544.1(0.120)]TJ 0 -1.0077 TD [(Never)-336.4(smoked)-5835.7(43)-2835.2(30.5)-3922.1(15)-2835.2(22.1)-3922.1(28)-2835.2(38.4)]TJ 0 -1.0135 TD [(Current)-331.7(smoker)-5392.3(49)-2835.2(34.8)-3922.1(26)-2835.2(38.2)-3922.1(23)-2835.2(31.5)]TJ T* [(Within)-331.1(last)-339.3(12)-330.2(mo.)-4515.5(5)-3335.2(3.5)-4422.2(4)-3335.2(5.9)-4422.2(1)-3335.2(1.4)]TJ -2.004 -1.3129 TD [(Depression)-341.1(Status)-335.4(\(PHQ2\))]TJ 2.004 -1.0135 TD [(Depressed)-7568.1(81)-2835.2(31)-4672.2(40)-2835.2(33.1)-3922.1(41)-2835.2(29.3)-4544.1(0.511)]TJ T* [(Not)-332.2(Depressed)-5235.9(180)-2836.2(69)-4672.2(81)-2835.2(66.9)-3922.1(99)-2835.2(70.7)]TJ -2.004 -1.3129 TD [(Age)-339(in)-330.4(years)-335.4(mean)-335.7(\(SD\))-3223.6(336)-1753.6(54.4)-334.6(\(10.6\))-1753.2(167)-1753.6(54.2)-334.6(\(11.2\))-1753.2(169)-1753.6(54.6)-334.6(\(10.0\))-7523.2(0.778)]TJ 0 -1.0135 TD [(Height)-336.5(in)-336.2(inches)-336.5(mean)-329.9(\(SD\))-1714.9(277)-1753.6(66.0)-334.6(\(4.1\))-2253.2(141)-1753.6(65.7)-334.6(\(4.4\))-2253.2(136)-1753.6(66.2)-334.6(\(3.8\))-8023.2(0.269)]TJ T* [(Weight)-337.9(in)-336.2(lbs.)-328.8(mean)-335.7(\(SD\))-2630.5(295)-1252.6(228.3)-335.6(\(63.4\))-1753.2(147)-1252.6(224.2)-335.6(\(67.2\))-1753.2(148)-1252.6(232.3)-335.6(\(59.3\))-7523.2(0.270)]TJ T* [(BMI)-338.8(mean)-335.7(\(SD\))-6563.6(324)-1753.6(36.8)-334.6(\(9.3\))-2253.2(158)-1753.6(36.4)-334.6(\(9.2\))-2253.2(166)-1753.6(37.1)-334.6(\(9.5\))-8023.2(0.508)]TJ 0 -1.0077 TD [(Hemoglobin)-335.9(A1c)-339(mean)-335.7(\(SD\))-1438.5(340)-1753.6(10.2)-334.6(\(1.7\))-2253.2(168)-1753.6(10.1)-334.6(\(1.7\))-2253.2(172)-1753.6(10.4)-334.6(\(1.7\))-8023.2(0.195)]TJ 0 -1.0135 TD [(LDL)-340.1(cholesterol)-337.2(mean)-329.9(\(SD\))-1766.7(237)-1753.6(99.7)-334.6(\(37.6\))-1753.2(117)-1753.6(99.9)-334.6(\(38.3\))-1753.2(120)-1753.6(99.6)-334.6(\(37.1\))-7523.2(0.937)]TJ T* [(HDL)-339.8(cholesterol)-337.2(mean)-335.7(\(SD\))-1657.3(240)-1753.6(42.6)-334.6(\(12.6\))-1753.2(119)-1753.6(44.2)-334.6(\(14.7\))-1753.2(121)-2502.2(41)-336(\(9.9\))-8023.2(0.051)]TJ 0 -1.0077 TD [(Triglycerides)-340.4(mean)-335.7(\(SD\))-3096.9(240)-1252.6(235.3)-335.6(\(214.4\))-1253.2(119)-1252.6(237.2)-335.6(\(224.8\))-1253.2(121)-1252.6(233.5)-335.6(\(204.6\))-7023.2(0.896)]TJ 0 -1.0135 TD [(Total)-335.9(cholesterol)-337.2(mean)-335.7(\(SD\))-1588.2(240)-1252.6(185.9)-335.6(\(50.2\))-1753.2(119)-1252.6(188.4)-335.6(\(52.3\))-1753.2(121)-1252.6(183.4)-335.6(\(48.1\))-7523.2(0.445)]TJ T* [(PHQ2-scores)-342.6(mean)-329.9(\(SD\))-3131.5(259)-2254.6(1.6)-333.6(\(1.8\))-2253.2(120)-2254.6(1.9)-333.6(\(1.9\))-2253.2(139)-2254.6(1.4)-333.6(\(1.9\))-8023.2(0.021)]TJ T* [(Systolic)-337.5(BP)-336.8(mean)-329.9(\(SD\))-3672.8(322)-2006.9(134)-331.2(\(19.6\))-1753.2(155)-1252.6(136.5)-335.6(\(20.4\))-1753.2(167)-1252.6(132.9)-335.6(\(18.7\))-7523.2(0.096)]TJ 0 -1.0077 TD [(Diastolic)-340.8(BP)-331(mean)-335.7(\(SD\))-3275.5(322)-1753.6(78.2)-334.6(\(11.3\))-1753.2(155)-1753.6(78.8)-334.6(\(10.2\))-1753.2(167)-1753.6(77.6)-334.6(\(12.2\))-7523.2(0.361)]TJ 8.7511 0 0 8.7511 67.748 83.5086 Tm [(Study)-362(participant)-366.4(demograhics)-366.2(and)-366.9(baseline)-365.8(comparison)-366.2(using)-360.6(chi-square)-368.4(analysis)-369.5(of)-359(control)-364.8(and)-366.9(intervention)-364.1(groups.)-368.4(Clinical)-366.2(data)-365.7(at)]TJ -.9134 -1.0236 TD [(baseline)-339.9(were)-328.9(compared)-333.7(using)-334.7(independent)-331.5(sample)]TJ /F9 1 Tf 21.1 0 TD (t)Tj /F4 1 Tf .6154 0 TD [(test)-335.7(for)-330.5(continuous)-335.2(outcomes.)]TJ -20.802 -1.0236 TD [(BMI,)-463.8(body)-461.8(mass)-463.8(index;)-464.6(BP,)-469(blood)-459.4(pressure;)-470.4(HDL,)-459.8(high-density)-466.2(lipoprotein;)-465.3(LDL,)-460.1(low-density)-469.7(lipoprotein;)-458.9(PQH-2,)-466.2(Patient)-463.2(Health)]TJ -.9134 -1.0301 TD [(Questionnaire;)-337.7(SD,)-332.8(standard)-332.1(deviation.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 59.7543 749.7069 Tm [(AUGMENTED)-339.9(DIABETES)-340.1(SELF-MANAGEMENT)-338.1(SUPPORT)-25527.3(523)]TJ ET endstream endobj 38 0 obj <>stream /GS1 gs BT /F4 1 Tf 9.843 0 0 9.843 62.022 725.1588 Tm 0 0 0 rg 0 Tc 0 Tw [(and)-442.2(had)-448(a)-440(HbA1c)]TJ /F5 1 Tf 8.0002 0 TD (>)Tj /F4 1 Tf .5529 0 TD [(8)-438.8(a)0(t)-447(the)-442.3(time)-444.8(of)-445.7(enrollment.)-444.6(Subjects)]TJ -8.5532 -1.1174 TD [(excluded)-536.6(from)-535.5(the)-534.5(study)-535.3(included)-535.5(individuals)-537.7(who)-534.1(were)]TJ 0 -1.1116 TD [(currently)-455.9(pregnant)-454.7(or)-445.7(undergoing)-455.8(cancer)-454.7(treatment;)-454(had)-453.7(a)]TJ T* [(diagnosis)-419.9(of)-416.9(end-stage)-422.2(renal)-422.6(disease)-419.9(or)-416.9(serious)-423.3(mental)-419.4(ill-)]TJ T* [(ness;)-329(or)-324.7(were)-330.1(receiving)-330.4(systemic)-329(treatment)-326(with)-328.1(prednisone)]TJ 0 -1.1174 TD [(or)-336.2(immunosuppressant)-334.2(therapy)-338.4(following)-333.7(organ)-334.9(transplant.)]TJ 1.0137 -1.1116 TD [(Randomization)-487(was)-483.2(centralized)-490.6(at)-487.3(the)-482.6(AADE)-486.3(ofce)-485.7(in)]TJ -1.0137 -1.1116 TD [(Chicago)-535.3(to)-538(ensure)-532.8(allocation)-539.2(concealment.)-541.2(When)-537.7(it)-532.4(was)]TJ 0 -1.1174 TD [(determined)-436.4(that)-432(individuals)-434.1(were)-433.8(eligible)-437.9(to)-428.5(participate)-437.7(in)]TJ 0 -1.1116 TD [(the)-263.8(study)-258.9(and)-263.6(had)-263.7(consented,)-264.4(a)-261.4(call)-266.2(was)-264.3(placed)-263.7(to)-261.5(the)-258(AADE)]TJ T* [(ofce)-312.9(where)-313.9(the)-315.6(blocked)-309.7(randomization)-318.9(chart)-313.2(for)-308.5(the)-315.6(center)]TJ 0 -1.1174 TD [(was)-552.3(used)-552.5(to)-549.5(assign)-548.9(the)-551.8(participant)-551.7(the)-551.8(next)-552.9(consecutive)]TJ 0 -1.1116 TD [(treatment)-395.1(condition.)-389.3(The)-391.6(individual)-392.8(was)-391(placed)-390.4(either)-395.1(in)-388.2(a)]TJ T* [(standard)-558.2(DSME)-554.4(progra)-7.7(m)-549.5(o)0(r)-555.1(a)-560.9(standard)-552.5(DSME)-560.2(program)]TJ T* [(augmented)-314.3(with)-305(the)-309.9(telephonic)-314.4(support)-307.1(provided)-309.6(by)-307.5(CHWs,)]TJ 0 -1.1174 TD [(known)-340.4(as)-343(health)-343.3(navigators.)-345.1(Demographics)-347(of)-336.2(study)-345.3(partic-)]TJ 0 -1.1116 TD [(ipants)-462.9(are)-466.4(shown)-461.2(in)-463.1(Table)-464.2(1.)-459.5(All)-465.2(study)-460.5(participants)-466.3(were)]TJ T* [(receiving)-336.2(care)-336.2(at)-337.6(one)-332.8(of)-336.2(the)-332.9(4)-329.4(FQHC)-335.3(study)-339.5(sites.)]TJ 1.0137 -1.1174 TD .0174 Tc [(Tel)4.7(e)3.6(ph)4.8(on)4.8(i)4.7(c)-365(s)5(u)4.8(pp)4.8(or)4.8(t)-358.2(w)-1.8(as)-357.9(pr)4.8(ov)4.8(i)4.7(d)-1(ed)-358.1(th)4.8(ro)4.8(u)4.8(g)-1(h)-358.1(t)4.7(he)-359.2(Nat)4.7(i)-1.1(o)4.8(n)4.8(a)-2.1(l)]TJ -1.0137 -1.1116 TD .0131 Tc [(Ce)-6.4(nt)-5.4(er)-247.1(fo)-5.3(r)-241.4(F)-5.1(ar)-5.2(mwo)-5.3(r).5(k)-5.3(e)-.7(r)-247.2(H)-.4(ea)-6.4(lt)-5.4(h,)-243.8(I)-5.2(n).5(c.)-249.5(\(N)-6.1(CFH)-6.1(\)).5(,)-243.8(w)-6.1(hi)-5.4(ch)-247.2(se)-6.4(rve)-6.4(d)]TJ T* .0149 Tc [(as)-429.5(a)-425.1(c)1.1(e)-4.6(n)2.3(traliz)-4.6(ed)-423.9(c)-4.6(a)1.1(ll)-424.1(ce)-4.6(nte)-4.6(r)-423.9(for)-423.9(a)-4.6(ll)-424.1(4)-429.7(s)2.5(ites.)-426.3(T)1.1(raining)-423.9(w)1.4(a)-4.6(s)]TJ 0 -1.1174 TD .013 Tc [(p)-5.4(rov)-5.4(id)-5.4(ed)-402.8(fo)-5.4(r)-402.8(h).4(ea)-6.5(lt)-5.5(h)-397(n)-5.4(av)-5.4(ig)-5.4(ato)-5.4(r).4(s)-5.2(,)-399.4(c)-6.5(ove)-6.5(ri)-5.5(ng)-402.8(DS)-5.2(ME)-404(de)-6.5(liv)-5.4(er)-5.3(y)]TJ 0 -1.1116 TD [(an)-5.4(d)-483.4(d)-5.4(at)-5.5(a)-484.6(e)-6.5(ntr)-5.3(y).4(.)-485.8(O)-6.2(n-)-5.3(si)-5.5(te)-490.4(tr)-5.3(ain)-5.4(i).3(n)-5.4(g)-483.4(o)-5.4(f)-483.4(h)-5.4(eal)-5.5(th)-489.2(na)-6.5(vi)-5.5(gat)-5.5(o).4(r)-5.3(s)-483.2(a)-6.5(t)]TJ T* .0165 Tc [(NCHF)-416.4(was)-410.6(c)-3(o)3.9(n)-1.9(d)3.9(u)-1.9(ct)3.8(ed)-410.8(by)-410.8(2)-416.6(c)2.7(reden)3.9(t)-2(i)3.8(a)-3(l)3.8(e)-3(d)-410.8(d)-1.9(i)3.8(a)2.7(betes)-416.4(e)2.7(du)3.9(ca-)]TJ 0 -1.1174 TD .0128 Tc [(t)-5.7(ors)-5.4(.)-232.5(P)-5.4(ri)-5.7(or)-235.9(t)-5.7(o)-236(the)-237.1(l)-5.7(iv)-5.6(e)-231.4(t)-5.7(ra)-6.7(in)-5.6(in)-5.6(g)-230.2(s)-5.4(es)-5.4(si)-5.7(on)-5.6(,)-232.5(t)-5.7(he)-237.1(he)-6.7(al)-5.7(th)-236(na)-6.7(vi)-5.7(gat)-5.7(o).2(r)-5.5(s)]TJ 0 -1.1116 TD .0131 Tc [(at)-385.5(NCF)-5.1(H)-380.5(to)-5.3(ok)-379.7(t)-5.4(h).5(e)-380.8(A)-.4(A)-6.1(D)-.4(E)-6.5().5(s)-379.5(o)-5.3(nli)-5.4(n).5(e)-380.8(F)-5.1(un)-5.3(dam)-6.5(e)-.7(n)-5.3(t).4(al)-5.4(s)-379.5(o).5(f)-385.4(D)-.4(ia)-6.4(-)]TJ T* .0128 Tc [(b)-5.6(e)-1(te)-6.7(s)-466.2(c)-1(o)-5.6(urs)-5.4(e)-467.5(a)-1(n)-5.6(d)-460.6(M)-6.5(o).2(t)-5.7(i).1(v)-5.6(a)-1(ti)-5.7(ng)-466.3(B)-6.6(e)-1(ha)-6.7(vi)-5.7(or)-466.3(Ch)-5.6(an)-5.6(ge)-467.5(re)-6.7(cor)-5.5(d).2(e)-6.7(d)]TJ T* [(we)-6.7(bi)-5.7(na)-6.7(r.)]TJ /F8 1 Tf 8.9663 0 0 8.9663 62.022 400.0251 Tm 0 Tc [(Data)-337.7(management)]TJ /F4 1 Tf 9.843 0 0 9.843 72 383.5841 Tm [(A)-347.5(data)-346.7(set)-344.2(was)-350.7(standardized)-352(across)-348.3(all)-350.3(participating)-346.7(sites)]TJ -1.0137 -1.1174 TD [(and)-298.2(a)-296(common)-298.2(data)-294.8(collection)-303(system,)-294.4(the)-298.3(Project)-298.1(IMPACT)]TJ 0 -1.1116 TD [(Database)-244.7(Explorer,)-245.1(was)-241.3(utilized)-242(by)-238.3(health)-239.6(care)-244(providers)-241.3(and)]TJ T* [(health)-493(navigators)-491.4(to)-491.9(streamline)-493.9(data)-490.7(organization)-495.1(and)-488.3(re-)]TJ 25.504 38.0429 TD [(portin)-6.8(g.)-344.4(The)-345.5(system)-348.6(was)-350.7(developed)-347.6(by)-347.8(the)-344.4(American)-354.3(Phar-)]TJ 0 -1.1174 TD [(macists)-535.3(Association)-527.9(Foundation)-530.7(as)-527.3(an)-527.5(extension)-530.7(of)-526.3(their)]TJ 0 -1.1116 TD [(work)-362.3(in)-353.7(Project)-361.4(IMPACT:)-357.2(Diabetes.)]TJ 7.3823 0 0 6.5614 459.8928 707.5841 Tm (9,10)Tj 9.843 0 0 9.843 476.3904 703.2188 Tm [(It)-353.6(provided)-361.4(secure,)]TJ -16.5937 -1.1116 TD [(role-b)-7.8(ased)-260(access)-258.5(for)-262.4(participant)-263.8(documentation)-261.3(of)-255.6(measures)]TJ T* [(outlined)-471.1(in)-463.1(the)-465.4(following)-466.2(section.)-468.6(The)-460.7(intervention)-471(group)]TJ 0 -1.1174 TD [(received)-330.3(regularly)-329.2(scheduled)-330.1(outbound)-325.7(phone)-329.2(calls)-330.4(from)-322.3(an)]TJ 0 -1.1116 TD [(NCFH)-243.2(health)-239.6(navigator)-242.9(who)-240.3(had)-234.9(access)-247(to)-238.5(information)-239.5(about)]TJ T* [(the)-281.1(individual)-283.4(and)-280.9(her)-280.9(or)-278.6(his)-279.7(participation)-283.4(in)-278.8(DSME)-277.9(through)]TJ 0 -1.1174 TD [(the)-246.5(Project)-246.3(IMPACT)-246.6(Database)-250.4(Explorer)-247.4(system.)-248.3(Initiation)-243.2(of)]TJ 0 -1.1116 TD [(outbound)-343(calls)-347.7(occurred)-346.3(and)-344.3(was)-339.2(documented)-349.9(while)-341.9(partic-)]TJ T* [(ipants)-347.7(were)-347.4(engaged)-345.3(in)-342.2(the)-344.4(DSME)-341.3(process)-343.7(to)-347.9(ensure)-342.8(conti-)]TJ 0 -1.1174 TD [(nuity)-328.3(between)-323.2(education)-330.5(and)-321.2(support.)-322.1(Calls)-324.6(were)-330.1(scheduled)]TJ 0 -1.1116 TD [(at)-366.4(a)-359.4(convenient)-366.1(day)-361.6(and)-361.6(time)-364.2(for)-360.3(the)-361.7(individual)-364(participant)]TJ T* [(ev)19.7(er)25.5(y)-283.3(2)-283.3(w)15.3(ee)18.5(ks)-267(fo)20.9(r)-283.3(3)-277.6(mo)19.6(n)16.2(t)0(h)20.7(s)0(.)-269.3(T)0(h)25.4(e)-284.5(fr)20.9(e)15(q)0(u)20.8(e)0(n)25.4(c)0(y)-274.1(o)16.2(f)-283.3(c)0(a)18.5(l)16(ls)-272.8(wa)24.6(s)-283.1(t)0(h)26.5(e)0(n)]TJ T* [(de)19.7(cr)25.5(ea)18.5(se)25.6(d)-369.7(t)16.1(o)-364(1)-369.7(c)15(a)0(l)19.5(l)-364.1(pe)25.4(r)-369.7(m)15(on)20.8(t)16(h)0(.)-355.9(T)0(h)25.4(e)-365.1(in)20.7(it)26.3(ia)19.6(l)-364.1(f)0(o)20.9(c)15(us)-353.4(of)-353.5(th)20.7(e)-365.1(c)0(o)25.4(n)0(-)]TJ 0 -1.1174 TD [(ve)19.7(rs)21.1(a)15(t)0(i)20.6(o)0(n)26.6(s)-260.1(du)26.6(ri)20.7(ng)-244.1(ea)24.3(ch)-251(c)15(a)0(l)19.6(l)-254.7(wa)18.8(s)-254.3(a)-261.4(d)16.2(i)0(s)20.9(c)0(u)25.4(s)0(s)21.2(i)0(o)20.7(n)-254.5(ab)19.7(o)16.2(u)0(t)-250(t)16(he)-245.3(le)19.6(ss)21.2(o)16.2(n)0(s)]TJ 0 -1.1116 TD [(le)19.5(ar)25.5(ne)19.7(d)-317.9(a)0(n)19.7(d)-317.9(go)20.8(al)25.3(s)-323.4(s)0(e)19.9(t)-318(du)20.8(r)16.2(i)0(n)20.7(g)-323.6(D)15.3(S)0(M)20.1(E)15(.)]TJ /F8 1 Tf 8.9663 0 0 8.9663 313.0582 520.5542 Tm (Measures)Tj /F4 1 Tf 9.843 0 0 9.843 323.0361 504.1133 Tm [(Demographic)-323.1(information)-320.1(collected)-326(on)-319(study)-316.5(participants)]TJ -1.0137 -1.1116 TD [(included)-316.7(age,)-308.6(sex,)-313(and)-309.7(race.)-310.8(In)-307.4(both)-309.8(groups,)-309.3(participation)-312.2(in)]TJ 0 -1.1174 TD [(diabe)-8(tes)-459.4(education)-462.9(sessions)-464.3(was)-460.2(tracked)-460.6(and)-459.5(in)-463.1(the)-459.6(inter-)]TJ 0 -1.1116 TD [(vention)-446.9(group,)-440.9(the)-442.3(number)-446.7(of)-439.9(telephonic)-446.9(support)-439.6(contacts)]TJ T* [(was)-316.2(documented.)-313.1(Clinical)-312.2(measures)-318.4(monitored)-312(were)-312.8(fasting)]TJ T* [(blood)-247.5(glucose,)-249.6(HbA1c;)-245.8(systolic)-251.9(and)-246.4(diastolic)-248.7(blood)-241.8(pressure;)]TJ 0 -1.1174 TD [(low-density)-400.2(lipoprotein)-399.7(\(LDL\))-400.4(cholesterol,)-399.3(high-density)-394.7(li-)]TJ 0 -1.1116 TD [(poprot)-6.7(ein)-367.5(\(HDL\))-371.2(cholesterol,)-370.5(and)-367.3(triglycerides)-375.2(from)-368.4(which)]TJ T* [(total)-508.2(cholesterol)-511.1(was)-512(calculated;)-508(height)-509.1(and)-505.6(weight)-510(from)]TJ 0 -1.1174 TD [(which)-353.3(body)-350(mass)-352(index)-352.4(\(BMI\))-352.9(was)-350.7(calculated.)-360.5(In)-347.7(addition,)]TJ 0 -1.1116 TD [(participant)-442.3(well-being)-440.8(was)-437.1(monitored)-438.8(over)-437.5(time)-439(using)-437.4(the)]TJ T* [(Patient)-430.7(Health)-430.5(Questionnaire.)-431.2(I)16.2(n)16.2(f)22(o)16.2(r)16.2(m)20.7(a)15(t)16(i)21.8(o)16.2(n)-410(o)16.2(n)-404.3(p)16.2(r)16.2(o)21.9(c)15(e)15(s)16.4(s)-404.1(m)15(e)20.8(a)15(-)]TJ 0 -1.1174 TD -.017 Tc [(sures)-282.8(w)-1.7(as)-282.8(collected)-283(t)-.9(o)-283(c)-2(o)4.9(m)-2(p)4.9(a)-2(re)-284.2(engagement)-283.2(i)4.8(n)-283(the)-284.2(c)3.8(ont)4.8(rol)-283.2(and)]TJ 0 -1.1116 TD -.0167 Tc [(interventio)5.2(n)-369.1(gro)5.2(ups.)-365.7(T)-1.7(h)5.2(i)-.6(s)-368.9(i)-.7(nclud)5.2(e)-1.7(d)-369.1(p)-.5(ar)5.3(ticipation)-369.1(i)5.1(n)-369.1(den)5.2(t)-.6(al)-369.3(ex-)]TJ T* -.0164 Tc [(ams)5.7(,)-267.5(e)-1.4(y)5.5(e)-266.3(exams,)-261.7(an)5.5(d)-265.2(foot)-259.5(exams;)-265.3(wheth)5.5(e)-1.4(r)-265.1(p)-.2(arti)5.4(cip)5.5(a)-1.4(nts)-265(h)5.5(ad)-265.2(had)]TJ ET 62.022 319.975 490.167 .28348 re f 62.022 95.301 490.167 .22675 re f 187.653 301.096 96.548 .28348 re f 302.797 301.096 96.548 .28348 re f 417.883 301.096 134.305 .28348 re f 62.022 283.408 490.167 .28348 re f BT /F7 1 Tf 9.845 0 0 9.845 127.1622 325.644 Tm 0 Tc (Table)Tj /F4 1 Tf 3.0002 0 TD (2.)Tj /F7 1 Tf 1.2496 0 TD [(Baseline)-332.4(and)]TJ /F4 1 Tf 6.3805 0 TD (1-)Tj /F7 1 Tf .835 0 TD [(Year)-332.8(Outcomes)-338.8(for)-332.2(Control)-337(and)-332(Intervention)-337.7(Groups)]TJ /F9 1 Tf -1.9752 -1.837 TD [(Control)-7684.2(Intervention)]TJ /F4 1 Tf 25.136 0 TD (P)Tj /F9 1 Tf .8868 0 TD (values)Tj -28.9482 -1.8197 TD [(N)-2305.4(Mean)-2401.7(SD)-2818.7(N)-2305.4(Mean)-2407.4(SD)-2398.4(Group)-2291.7(Time)-2292.1(Interaction)]TJ /F4 1 Tf -13.1813 -1.8946 TD [(Baseline)-340.8(A1c)-7301(168)-2404.3(10.1)-2902.9(1.7)-1888.4(172)-2404.3(10.4)-2902.9(1.7)-2061.1(0.567)]TJ /F5 1 Tf 40.6381 0 TD (<)Tj /F4 1 Tf .5528 0 TD [(0.001)-2996(0.207)]TJ -41.1909 -1.0135 TD [(1-Year)-337.3(A1c)-12385.8(8.7)-2901.9(1.8)-6287.9(8.7)-2907.7(1.9)]TJ T* [(Baseline)-340.8(BMI)-7082(158)-2404.3(36.4)-2902.9(9.2)-1888.4(166)-2404.3(37.1)-2902.9(9.5)-2061.1(0.455)-2615.9(0.011)-2996(0.517)]TJ 0 -1.0077 TD [(1-Year)-337.3(BMI)-11665.8(36.0)-2902.9(9.1)-5792.7(36.9)-2902.9(9.1)]TJ 0 -1.0135 TD [(Baseline)-340.8(HDL)-6916(118)-2404.3(44.3)-2401.9(14.8)-1889.4(119)-2404.3(41.1)-2401.9(10.0)-2062.1(0.212)-2615.9(0.393)-2996(0.077)]TJ T* [(1-Year)-337.3(HDL)-11499.8(43.7)-2401.9(13.6)-5793.7(42.9)-2401.9(14.8)]TJ T* [(Baseline)-340.8(LDL)-7020(111)-1903.3(100.5)-2402.9(38.5)-1889.4(114)-2404.3(98.9)-2401.9(36.1)-2062.1(0.690)-2615.9(0.015)-2996(0.980)]TJ 0 -1.0077 TD [(1-Year)-337.3(LDL)-11603.8(94.9)-2401.9(38.2)-5793.7(93.2)-2401.9(32.7)]TJ 0 -1.0135 TD [(Baseline)-340.8(Triglycerides)-3617(118)-1903.3(237.4)-1901.9(225.8)-1890.4(120)-1903.3(231.5)-1901.9(204.3)-2063.1(0.658)-2615.9(0.004)-2996(0.741)]TJ T* [(1-Year)-337.3(Triglycerides)-7699.8(208.2)-1901.9(172.7)-5293.7(194.9)-1901.9(141.6)]TJ T* [(Baseline)-340.8(Total)-330.1(Cholesterol)-1891.9(118)-1903.3(188.8)-2402.9(52.3)-1889.4(120)-1903.3(183.3)-2402.9(48.3)-2062.1(0.445)-2615.9(0.079)-2996(0.001)]TJ 0 -1.0077 TD [(1-Year)-337.3(Total)-335.9(Cholesterol)-5968.9(175.0)-2402.9(46.4)-5292.7(172.3)-2402.9(40.5)]TJ 0 -1.0135 TD [(Baseline)-340.8(Systolic)-331.7(BP)-4189.3(155)-1903.3(136.5)-2402.9(20.4)-1889.4(167)-1903.3(132.9)-2402.9(18.7)-2062.1(0.203)-2615.9(0.217)-2996(0.211)]TJ T* [(1-Year)-337.3(Systolic)-337.5(BP)-8266.3(133.5)-2402.9(16.8)-5292.7(132.9)-2402.9(18.0)]TJ T* [(Baseline)-340.8(Diastolic)-335.1(BP)-3791.9(155)-2404.3(78.8)-2401.9(10.2)-1889.4(167)-2404.3(77.6)-2401.9(12.2)-2062.1(0.252)-2615.9(0.842)-2996(0.987)]TJ 0 -1.0077 TD [(1-Year)-337.3(Diastolic)-335.1(BP)-8375.7(78.9)-2401.9(10.7)-5793.7(77.8)-2401.9(10.7)]TJ 0 -1.0135 TD [(Baseline)-340.8(PHQ-2)-6145(120)-2905.3(1.9)-2901.9(1.9)-1888.4(139)-2899.5(1.4)-2907.7(1.9)-2061.1(0.377)-2615.9(0.003)-2996(0.031)]TJ T* [(1-Year)-337.3(PHQ-2)-11229.8(1.3)-2901.9(1.7)-6287.9(1.4)-2907.7(1.9)]TJ 8.7511 0 0 8.7511 70.0157 83.4519 Tm [(Baseline)-303.5(measurements)-310.3(and)-302.2(1-year)-309.9(outcomes)-305.2(for)-304.6(control)-306.5(and)-308.6(intervention)-305.8(groups)-300.9(with)]TJ /F9 1 Tf 35.2034 0 TD (P)Tj /F4 1 Tf .9199 0 TD [(value)-306.2(main)-310.3(effects)-307.1(and)-302.2(interactions)-311.8(for)-304.6(each)-309.8(of)]TJ -37.0368 -1.0236 TD [(the)-333.3(repeated)-336(measures)-337(utilizing)-327.7(a)-336.9(1-way)-333.1(analysis)-337.1(of)-333.1(variance.)]TJ .9134 -1.0236 TD [(BMI,)-463.8(body)-461.8(mass)-463.8(index;)-464.6(BP,)-462.6(blood)-465.8(pressure;)-463.9(HDL,)-466.3(high-density)-466.2(lipoprotein;)-458.8(LDL,)-466.6(low-density)-463.2(lipoprotein;)-465.3(PQH-2,)-466.2(Patient)-463.2(Health)]TJ -.9134 -1.0236 TD [(Questionnaire;)-337.7(SD,)-332.8(standard)-332.1(deviation.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 62.022 749.6502 Tm (524)Tj 47.6052 0 TD [(BLUML)-334.7(ET)-338.7(AL.)]TJ ET endstream endobj 42 0 obj <>stream /GS1 gs BT /F4 1 Tf 9.843 0 0 9.843 59.7543 577.4739 Tm 0 0 0 rg -.0156 Tc 0 Tw [(an)-241.3(inu)6.3(enz)5.2(a)-242.5(or)-247.1(p)6.3(n).6(eu)6.3(moc)5.2(o).6(cc)5.2(al)-241.5(vac)5.2(c)-.6(in)6.3(e;)-241.5(and)-241.3(t).5(h)6.3(e)-248.2(t)6.2(o).6(ta)5.2(l)-247.2(n)6.3(umb)6.3(e)-.6(r)-241.3(o).6(f)]TJ 0 -1.1116 TD -.0162 Tc [(visi)5.6(ts)-305.1(to)-305.3(the)-306.4(p)5.7(arti)5.6(cip)5.7(a)-1.2(nt)5.6(s)-305.3(FQHC.)-307.6(T)4.5(he)-306.4(number)-305.2(a)4.6(nd)-305.3(cat)5.6(ego)5.7(r)0(y)-305.3(o)0(f)]TJ T* [(AADE7)-299.6(Self)5.7(-care)-300.8(B)-1.1(eh)5.6(avi)5.5(ors)-299.4(goals)-305.2(s)5.8(e)-1.3(t)-305.5(d)5.6(uri)5.5(ng)-299.6(the)-300.8(s).1(tu)5.6(dy)-305.4(p)5.6(e)-1.3(ri)5.5(od)]TJ 0 -1.1174 TD -.0166 Tc [(as)-265.2(well)-259.7(as)-259.4(the)-260.8(n)-.4(u)5.3(m)-1.6(ber)-265.3(a)4.2(nd)-265.4(categor)5.4(y)-265.4(o)5.3(f)-265.3(s)-.2(elf-care)-260.8(g)-.4(o)5.3(a)-1.6(ls)-259.4(ach)5.3(iev)5.3(e)-1.6(d)]TJ 0 -1.1116 TD -.0158 Tc [(also)-327.9(we)5(re)-329.1(rec)5(ord)6.1(ed.)-330.3(P)6.3(arti)6(cip)6.1(a)-.8(nt)-328.1(sa)5(tisf)6.2(act)6(ion)-327.9(w)-.5(as)-327.7(ev)6.1(alu)6.1(a)-.8(te)5(d)-333.7(p)6.1(re)]TJ T* -.0166 Tc [(and)-426.6(pos)5.5(t)-432.5(i)5.2(nterven)5.3(tio)5.3(n)-432.4(u)-.4(s)5.5(i)-.5(ng)-426.6(a)-427.8(6-qu)5.3(est)5.2(i)-.5(on)-426.6(sur)5.4(v)-.4(ey,)-429(w)4.5(hich)-432.4(was)]TJ 0 -1.1174 TD -.0162 Tc [(graded)-328.3(u)0(sin)5.7(g)-334.1(a)-329.5(L)-1.2(ik)5.7(ert)-328.5(s).2(co)5.7(re)-335.2(f)5.8(rom)-329.5(1)-334.1(t)5.6(o)-334.1(5)0(.)]TJ 1.0137 -1.1116 TD .013 Tc [(This)-379.6(study)-385.5(w)5.3(a)-.8(s)-385.3(d).4(esig)6.1(ned)-385.5(t).3(o)-379.8(e)-.8(xam)4.9(i).3(ne)-386.7(e)5(f).4(cacy)-379.8(of)-385.5(an)-379.8(in-)]TJ -1.0137 -1.1116 TD .0128 Tc [(tervention)-483.6(i).1(n)-483.6(a)-484.8(real-wo)5.9(r).2(ld)-489.4(si)5.8(tuation.)-486(Therefore,)-480.2(t).1(he)-484.8(data)]TJ 0 -1.1174 TD [(used)-443.3(for)-437.5(the)-444.5(1-year)-443.3(follow-)6(up)-443.3(visit)-437.7(w)-.7(ere)-444.5(t).1(ak)5.9(en)-443.3(from)-438.8(the)]TJ 0 -1.1116 TD [(visit)-414.7(t)0(hat)-414.7(w)-.8(as)-414.4(cl)5.7(osest)-414.7(t)0(o)-414.6(3)5.8(65)-414.6(days)-408.7(after)-414.6(b).1(aseline)-415.8(but)-409(was)]TJ T* .0129 Tc [(accepted)-374.1(from)-381.1(v)6(i).2(sits)-379.7(betwe)4.9(e)-.9(n)-379.9(6)-379.9(a)4.9(nd)-379.9(18)-379.9(m)4.8(onths)-379.7(foll)5.9(o).3(wing)]TJ 0 -1.1174 TD [(the)-334.9(b).3(asel)5.9(ine)-334.9(v).3(isit.)]TJ /F8 1 Tf 8.9663 0 0 8.9663 59.7543 414.5952 Tm 0 Tc [(Statistical)-336.1(analysis)]TJ /F4 1 Tf 9.843 0 0 9.843 69.7323 398.1542 Tm [(Descriptive)-615.7(statistics)-612.4(for)-608(the)-609.4(control)-613.9(and)-609.2(intervention)]TJ -1.0137 -1.1116 TD [(groups)-490.2(were)-491.4(compared)-491.6(using)-489.3(chi-square)-492.4(analysis)-489.1(and)-488.3(are)]TJ 0 -1.1174 TD [(shown)-311.5(in)-307.6(Table)-308.7(1.)-309.8(Baseline)-307.1(clinical)-312.3(data)-312.1(for)-308.5(the)-304.1(control)-314.4(and)]TJ 0 -1.1116 TD [(intervention)-753.3(groups)-749.4(were)-750.6(compared)-750.7(using)-748.4(independent)]TJ T* (sample)Tj /F9 1 Tf 3.1448 0 TD (t)Tj /F4 1 Tf .5817 0 TD [(test)-299.4(for)-297(continuous)-300.2(outcomes)-300.3(and)-304(none)-299.3(were)-301.3(found)]TJ -3.7265 -1.1116 TD [(to)-336.4(differ)-336.1(\(Table)-332.8(1\).)]TJ 26.5234 23.7818 TD [(Changes)-448.6(in)-451.6(clinical)-450.6(outcomes)-450(over)-454.8(time)-450.6(between)-449.9(the)-448.1(2)]TJ -1.0137 -1.1116 TD [(groups)-328.9(were)-330.1(compared)-336(using)-328(repeated)-330.3(measures)-335.7(analysis)-333.6(of)]TJ T* [(variance)-560.7(\(ANOVA\).)-556.9(Table)-556.3(2)-559.8(presents)-558(the)-557.5(measurements)]TJ 0 -1.1174 TD [(taken)-370.8(at)-366.4(baseline)-375.2(and)-367.3(1)-369.7(year)-369.6(along)-369.7(with)]TJ /F9 1 Tf 16.8299 0 TD (P)Tj /F4 1 Tf .9849 0 TD [(values)-371.7(for)-366.1(main)]TJ -17.8148 -1.1116 TD -.0165 Tc [(effects)-564.6(a)4.3(nd)-564.8(in)5.4(ter)5.5(act)5.3(ions)-558.8(for)-564.7(each)-559(of)-564.7(t)5.3(h)-.3(e)-565.9(r)-.3(epeated)-559(measur)5.5(e)]TJ T* [(ANOVAs.)-371.4(M)4.4(ann-)5.4(Wh)5.3(itney)-374.8(U)-369.9(tests)-368.8(w)-1.3(ere)-370.2(u)-.4(sed)-369(t)-.5(o)-369(c)4.2(omp)5.3(a)-1.6(re)-370.2(th)5.3(e)]TJ 0 -1.1174 TD -.0157 Tc [(t)6.1(a)-.7(lli)6.1(es)-247(f)6.3(o).5(r)-247.2(t)6.1(he)-248.3(t)6.1(o).5(tal)-241.6(num)5(be)5.1(r)-247.1(o).5(f)-241.4(eac)5.1(h)-247.2(p).5(r)6.3(o).5(ce)5.1(ss)-247(me)5.1(asu)6.2(r).5(es)-241.2(\(Ta)5.1(b).5(le)-242.6(3\).)]TJ 0 -1.1116 TD -.0168 Tc [(Chi-s)5.3(quare)-272.5(t)5(e)-1.8(sts)-265.4(w)-1.5(ere)-272.5(u)5.1(sed)-265.6(t)-.7(o)-265.6(c)-1.8(ompar)5.2(e)-272.5(th)5.1(e)-272.5(n)5.1(umb)5.1(e)-1.8(r)-271.3(o)5.1(f)-271.3(s)-.4(elf-)5.2(care)]TJ T* -.0166 Tc [(g)5.3(o)-.4(als)-386.1(s)-.2(et)-392.2(and)-386.3(ach)5.3(iev)5.3(e)-1.6(d)-386.3(\()-.4(Table)-387.5(4)-.4(\))5.4(.)-388.7(Pearso)5.3(n)-392.1(c)4.2(orrelat)5.2(i)-.6(on)-386.3(co)5.3(ef)5.5(-)]TJ 0 -1.1174 TD -.0168 Tc [(cien)5.1(ts)-294.2(were)-289.8(used)-294.4(t)5(o)-294.4(measure)-289.8(th)5.1(e)-295.5(n)5.1(umb)5.1(e)-1.8(r)-288.6(o)-.6(f)-294.3(t)5(elepho)5.1(nic)-289.8(s)-.4(up)5.1(por)5.2(t)]TJ 0 -1.1116 TD -.0157 Tc [(c)5.1(onta)5.1(c)-.7(ts)-293.1(with)-293.3(succ)5.1(ess)-293.1(i).4(n)-299(a)-.7(c)5.1(h).5(ie)5.1(vin)6.2(g)-299(the)-294.4(s).7(et)-299.2(g)6.2(o).5(al)-299.2(f)6.3(o).5(r)-299(e)5.1(ach)-299(o)6.2(f)-299(the)]TJ T* -.0167 Tc [(AADE7)-294.3(s)-.3(elf)5.3(-)-.5(care)-295.4(behav)5.2(i)-.6(ors)-294.1(\()5.3(Tab)]TJ 12.919 0 TD [(le)-295.4(5\))-294.2(as)-294.1(wel)5.1(l)-294.4(as)-294.1(for)-294.2(r)5.3(e)-1.7(spo)5.2(n)-.5(ses)]TJ -12.919 -1.1174 TD [(t)5.1(o)-311.5(the)-312.7(q)-.5(u)5.2(e)-1.7(st)5.1(ions)-311.3(i)5.1(n)-311.5(the)-312.7(p)5.2(atient)-311.7(satisf)5.3(act)5.1(ion)-311.5(s)-.3(u)5.2(rvey,)-313.9(which)-311.5(w)-1.4(ere)]TJ 0 -1.1116 TD -.017 Tc [(scored)-334.9(u)-.8(s)5.1(i)-.9(ng)-329.1(a)-336(L)3.7(ikert)-335(s)-.6(core)-330.3(fro)4.9(m)-336.1(1)-329.1(to)-329.1(5)-334.9(\()-.8(Tabl)4.8(e)-336(6)4.9(\).)]TJ /F3 1 Tf 8.9663 0 0 8.9663 310.8472 403.6534 Tm 0 Tc (Results)Tj /F4 1 Tf 9.843 0 0 9.843 320.8251 387.2125 Tm [(The)-397.3(mean)-399.6(age)-397.3(of)-393.8(the)-402(participants)-397.1(was)-402.6(54.6)-392.6(years)-399.3(in)-399.7(the)]TJ -1.0137 -1.1174 TD [(intervention)-545.9(group)-546.9(and)-545.9(54.2)-542.4(years)-543.3(in)-549.5(the)-540.2(control)-550.5(group.)]TJ 0 -1.1116 TD [(Distribution)-291(of)-295.9(sexes)-295.4(was)-293.1(similar)-292.5(between)-294.4(groups)-294.4(\(Table)-292.5(1\).)]TJ T* [(The)-316.7(groups)-323.2(did)-320.2(not)-320.2(differ)-318.8(signicantly)-326.7(by)-319(race,)-322.3(with)-316.6(almost)]TJ T* [(half)-351.2(of)-347.7(the)-350.2(total)-352.6(study)-351(population)-352.4(being)-346.6(white,)-351.1(followed)-356.7(by)]TJ ET 59.754 719.49 490.167 .22668 re f 59.754 614.324 490.167 .22681 re f 210.954 700.611 107.093 .22681 re f 360.567 700.611 124.724 .22681 re f 59.754 682.923 490.167 .22675 re f BT /F7 1 Tf 9.845 0 0 9.845 106.0724 725.1588 Tm (Table)Tj /F4 1 Tf 3.0002 0 TD (3.)Tj /F7 1 Tf 1.2496 0 TD [(Comparison)-336.2(of)-337(Control)-331.2(and)-332(Intervention)-337.7(Groups)-337(Process)-334.5(Measures)-331.9(Over)-338.6(Time)]TJ /F9 1 Tf 8.2635 -1.8427 TD [(Control)-330.6(\(N)]TJ /F5 1 Tf 4.6126 0 TD (=)Tj /F9 1 Tf .7198 0 TD [(225\))-8025.6(Intervention)-338.2(\(N)]TJ /F5 1 Tf 16.2679 0 TD (=)Tj /F9 1 Tf .7141 0 TD (221\))Tj -23.4142 -1.8197 TD [(Mean)-5845.3(SD)-6296.9(Mean)-6743.6(SD)]TJ /F4 1 Tf 32.2709 0 TD (P)Tj -48.389 -1.8946 TD [(Dental)-337.7(Exams)-10891.9(0.1)-6351.3(0.3)-6541.3(0.2)-7497.2(0.5)-5522(0.239)]TJ 0 -1.0135 TD [(Eye)-339.3(Exams)-12003.3(0.9)-6351.3(0.9)-6541.3(0.9)-7497.2(1.0)-5522(0.472)]TJ 0 -1.0077 TD [(Foot)-338(Exams)-11732.7(1.4)-6351.3(0.9)-6541.3(1.4)-7497.2(0.9)-5522(0.259)]TJ 0 -1.0135 TD [(Inuenza)-339.5(Vaccination)-7716.1(0.9)-6351.3(0.9)-6541.3(1.00)-6997.2(0.8)-5522(0.205)]TJ T* [(Pneumococcal)-341.4(Vaccination)-5591.2(0.5)-6351.3(0.6)-6541.3(0.5)-7497.2(0.6)-5522(0.740)]TJ T* [(Number)-337.3(of)-336(Visits)-9514.3(3.6)-6351.3(1.7)-6541.3(3.9)-7497.2(1.7)-5522(0.036)]TJ 8.7511 0 0 8.7511 67.748 602.5321 Tm [(SD,)-332.8(standard)-332.1(deviation.)]TJ ET 59.754 312.661 490.167 .22681 re f 59.754 77.556 490.167 .22684 re f 219.572 293.783 65.65 .22684 re f 318.841 293.783 65.65 .22684 re f 418.167 293.783 75.968 .22684 re f 59.754 276.094 490.167 .22675 re f 59.754 195.137 490.167 .28346 re f 219.572 173.764 65.65 .28342 re f 318.841 173.764 65.65 .28342 re f 418.167 173.764 75.968 .28342 re f 59.754 156.076 490.167 .28348 re f BT /F7 1 Tf 9.845 0 0 9.845 204.7747 318.3306 Tm (Table)Tj /F4 1 Tf 3.0002 0 TD (4.)Tj /F7 1 Tf 1.2496 0 TD [(Self-Care)-333.2(Goals)-333.5(Set)-336.8(and)-332(Achieved)]TJ /F9 1 Tf -.4722 -1.8427 TD [(Total)-7474(Control)-6601.6(Intervention)]TJ -18.508 -1.8139 TD [(AADE)-336.5(self-care)-340.7(goals)-333.2(set)-6292.5(N)-4292.1(%)-4297.9(N)-4292.1(%)-4557(N)-4816.1(%)]TJ /F4 1 Tf 48.389 0 TD (P)Tj -48.389 -1.9003 TD [(Healthy)-338.7(Eating)-10097.6(327)-3417.8(73.8)-3415.4(159)-3417.8(71.6)-3680.3(168)-3947.6(76.0)-3680.3(0.293)]TJ 0 -1.0077 TD [(Being)-335.5(Active)-10829.8(237)-3417.8(53.5)-3415.4(111)-3417.8(50.0)-3680.3(126)-3947.6(57.0)-3680.3(0.139)]TJ 0 -1.0135 TD [(Monitoring)-11672.3(227)-3417.8(51.2)-3415.4(116)-3417.8(52.3)-3680.3(111)-3947.6(50.2)-3680.3(0.670)]TJ T* [(Taking)-336.7(Medications)-8100.6(197)-3417.8(44.5)-3415.4(106)-3417.8(47.7)-4181.3(91)-3946.6(41.2)-3680.3(0.164)]TJ T* [(Problem)-337.5(Solving)-9387.8(101)-3417.8(22.8)-3916.4(43)-3416.8(19.4)-4181.3(58)-3946.6(26.2)-3680.3(0.085)]TJ 0 -1.0077 TD [(Reducing)-339.7(Risk)-10220.6(169)-3417.8(38.1)-3916.4(80)-3416.8(36.0)-4181.3(89)-3946.6(40.3)-3680.3(0.359)]TJ 0 -1.0135 TD [(Healthy)-338.7(Coping)-10274.6(62)-3416.8(14.0)-3916.4(28)-3416.8(12.6)-4181.3(34)-3946.6(15.4)-3680.3(0.400)]TJ /F9 1 Tf 18.508 -2.1479 TD [(Total)-7474(Control)-6601.6(Intervention)]TJ -18.508 -2.0212 TD [(AADE)-336.5(self-care)-340.7(goals)-333.2(achieved)-3836.5(N)-4292.1(%)-4297.9(N)-4292.1(%)-4557(N)-4816.1(%)]TJ /F4 1 Tf 48.389 0 TD (P)Tj -48.389 -1.9464 TD [(Healthy)-338.7(Eating)-10097.6(142)-3417.8(43.4)-3916.4(64)-3416.8(40.3)-4181.3(78)-3946.6(46.4)-3680.3(0.260)]TJ 0 -1.0135 TD [(Being)-335.5(Active)-11330.8(86)-3416.8(36.3)-3916.4(31)-3416.8(27.9)-4181.3(55)-3946.6(43.7)-3680.3(0.012)]TJ T* [(Monitoring)-12173.3(94)-3416.8(41.4)-3916.4(44)-3416.8(37.9)-4181.3(50)-3946.6(45.0)-3680.3(0.277)]TJ 0 -1.0077 TD [(Taking)-336.7(Medications)-8601.6(90)-3416.8(45.7)-3916.4(42)-3416.8(39.6)-4181.3(48)-3946.6(52.7)-3680.3(0.065)]TJ 0 -1.0135 TD [(Problem)-337.5(Solving)-9888.8(63)-3416.8(62.4)-3916.4(29)-3416.8(67.4)-4181.3(34)-3946.6(58.4)-3680.3(0.366)]TJ T* [(Reducing)-339.7(Risk)-10721.6(90)-3416.8(53.3)-3916.4(39)-3416.8(48.8)-4181.3(51)-3946.6(57.3)-3680.3(0.266)]TJ T* [(Healthy)-338.7(Coping)-10274.6(28)-3416.8(45.2)-3916.4(10)-3416.8(35.7)-4181.3(18)-3946.6(52.9)-3680.3(0.175)]TJ 8.7511 0 0 8.7511 67.748 65.537 Tm [(Comparison)-335.1(of)-333.1(control)-332.4(and)-328.1(intervention)-338.2(gourps)-326.8(utilizing)-334.2(chi-square)-336(tests)-333(of)-333.1(the)-333.3(above)-333.4(AADE-7)-337.9(self-care)-330.4(behaviors)-337.4(set)-331.7(and)-334.6(achieved.)]TJ 0 -1.0236 TD [(AADE,)-331.3(American)-334.7(Association)-334.6(of)-333.1(Diabetes)-335.7(Educators.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 59.7543 749.7069 Tm [(AUGMENTED)-339.9(DIABETES)-340.1(SELF-MANAGEMENT)-338.1(SUPPORT)-25527.3(525)]TJ ET endstream endobj 46 0 obj <>stream /GS1 gs BT /F4 1 Tf 9.843 0 0 9.843 62.022 444.9258 Tm 0 0 0 rg 0 Tc 0 Tw [(Hispanic,)-487.8(African)-489(American/black,)-487.9(and)-482.5(Native)-488.1(American,)]TJ 0 -1.1116 TD [(with)-333.8(Other)-335.9(and)-332.8(Not)-338.4(Specied)-334.7(accounting)-337.3(for)-331.5(less)-339.4(than)-334(1%.)]TJ 1.0137 -1.1174 TD [(There)-504.3(were)-508.7(signicant)-503(improvements)-507.6(in)-503.4(HbA1c,)-507.2(BMI,)]TJ -1.0137 -1.1116 TD [(LDL,)-395.9(triglycerides,)-395.9(and)-390.4(depression)-393.2(screening)-399.2(scores)-394.4(in)-388.2(the)]TJ T* [(year)-317.7(following)-310.7(DSME.)-315.9(However,)-314.7(there)-313.2(were)-318.6(no)-313.2(statistically)]TJ 0 -1.1174 TD [(signicant)-341.7(difference-in-differences)-347.8(between)-334.7(the)-338.7(groups)-334.7(for)]TJ 0 -1.1116 TD [(HbA1c,)-317.1(BMI,)-313.9(HDL,)-314.9(LDL,)-309.5(triglycerides,)-321(and)-309.7(blood)-316.7(pressure)]TJ T* [(\(Table)-494(2\).)-489.4(No)-492.6(signicant)-497.2(change)-493.9(in)-486.1(either)-493(systoli)-7.7(c)-486.1(blood)]TJ 0 -1.1174 TD [(pressure)-241.1(or)-232.6(diastolic)-237.2(blood)-236(pressure)-241.1(were)-238(observed)-235.5(following)]TJ 0 -1.1116 TD [(DSME)-462.2(for)-458.3(either)-464.2(group.)-458.2(Total)-463.1(cholesterol)-465(and)-459.5(depression)]TJ T* [(screening)-301.3(score)-301.3(seemed)-304.9(to)-296.1(show)-298.8(a)-301.8(signicant)-301.4(group)-299.2(by)-301.7(time)]TJ T* (interaction;)Tj /F9 1 Tf 4.9188 0 TD (P)Tj /F5 1 Tf .7776 0 TD (=)Tj /F4 1 Tf .72 0 TD [(0.001)-336.1(and)]TJ /F9 1 Tf 4.3659 0 TD (P)Tj /F5 1 Tf .7833 0 TD (=)Tj /F4 1 Tf .72 0 TD [(0.031,)-328.1(respectivel)-11.2(y.)]TJ -11.2717 -1.1174 TD [(Comparison)-475.1(of)-468.7(engagement)-477.8(in)-474.6(individual)-473.5(process)-476.1(mea-)]TJ -1.0137 -1.1116 TD [(sures)-369.1(associated)-366.9(with)-368.4(the)-361.7(AADE7)-372.2(self-care)-365.7(behavior)-368.3(of)-365(re-)]TJ 25.504 42.9444 TD [(ducing)-244.1(risks)-241.4(did)-239.6(not)-245.3(differ)-244(for)-239.4(participants)-247.4(in)-238.5(the)-240.7(intervention)]TJ 0 -1.1174 TD [(and)-286.7(control)-285.6(cohorts)-285.2(\(Table)-286.7(3\).)-282.1(Total)-290.4(number)-285.4(of)-278.6(FQHC)-289.2(visits)]TJ 0 -1.1116 TD [(for)-481.3(individuals)-474.4(in)-480.4(the)-476.9(intervention)-476.8(group)-477.8(was)-477.4(statistically)]TJ T* [(greater)-339.6(than)-334(for)-337.3(those)-334.9(in)-330.6(the)-332.9(control)-337.4(cohort,)]TJ /F9 1 Tf 18.1373 0 TD (P)Tj /F5 1 Tf .7833 0 TD (=)Tj /F4 1 Tf .72 0 TD (0.036.)Tj -18.6269 -1.1116 TD [(When)-411(examining)-411.2(goal-setting)-413.3(preference,)-417.6(there)-411.1(were)-410.7(no)]TJ -1.0137 -1.1174 TD [(differences)-535(in)-520.7(the)-528.7(proportion)-523.8(of)-520.5(goals)-530.7(set)-522.8(in)-526.5(any)-522.8(of)-526.3(the)]TJ 0 -1.1116 TD -.0158 Tc [(AADE)4.9(7)-431.6(cate)5(gor)6.2(ies)-431.4(b).4(et)6(wee)5(n)-437.4(t)6(h).4(e)-432.8(gro)6.1(ups.)-433.9(H)5.3(owe)5(v).4(er)6.2(,)-433.9(a)-438.5(si)6(gni)6(-)]TJ T* -.0164 Tc [(can)5.5(tly)-340(greater)-340(number)-340(o)-.2(f)-340(t)5.4(hose)-341.2(i)5.4(n)-345.8(t)5.4(he)-341.2(int)5.4(e)-1.4(rv)5.5(ent)5.4(i)-.3(on)-340(gr)5.6(oup)-340(su)5.5(c-)]TJ 0 -1.1174 TD -.0168 Tc [(cess)5.3(full)5(y)-334.7(met)-334.8(t)-.7(heir)-334.6(goal)-334.8(for)-334.6(b)5.1(e)-1.8(in)5.1(g)-334.7(act)5(ive:)]TJ /F9 1 Tf 16.4324 0 TD 0 Tc (P)Tj /F5 1 Tf .766 0 TD (=)Tj /F4 1 Tf .7027 0 TD -.0165 Tc [(0)5.4(.)3.1(012)-334.4(\(Tabl)5.3(e)-335.5(4\).)]TJ -17.9012 -1.1116 TD -.0167 Tc [(Interest)5.1(i)-.6(ng)5.2(ly,)-244.8(for)-248.2(6)-242.4(o)-.5(f)-248.2(t)-.6(h)5.2(e)-249.3(7)-248.2(A)-1.4(ADE7)-242.4(self)5.3(-care)-249.3(b)-.5(ehav)5.2(iors)-248(as)-248(well)]TJ T* -.0161 Tc [(as)-356.8(f)5.9(o).1(r)-351.2(t)0(he)-352.4(to)5.8(tal)-351.4(g).1(o)5.8(a)-1.1(ls)-351.1(set)5.7(,)-353.6(there)-352.4(w)-.8(as)-351.1(a)-352.4(pos)6(itiv)5.8(e)-352.4(c)-1.1(orr)5.9(elatio)5.8(n)-357(b)5.8(e-)]TJ 0 -1.1174 TD -.0165 Tc [(tween)-276.8(n)5.4(umb)5.4(e)-1.5(r)-276.7(o)5.4(f)-276.8(t)-.4(elep)5.4(honi)5.3(c)-277.9(s)-.1(u)5.4(ppo)5.4(rt)-276.9(contacts)-270.8(and)-271(s)-.1(ucces)5.6(s)-276.6(w)-1.2(i)5.3(t)-.4(h)]TJ 0 -1.1116 TD [(attaini)5.3(n)-.3(g)-334.4(t)5.3(he)-329.8(goal)-328.7(\()-.3(Tabl)5.3(e)-335.5(5)-.3(\))5.5(.)]TJ 1.0137 -1.1116 TD 0 Tc [(Patient)-384.6(satisfaction)-379.7(as)-383.3(reected)-382(in)-376.7(individual)-381.3(or)-382.3(total)-375.7(re-)]TJ -1.0137 -1.1116 TD [(sponses)-261.7(to)-261.5(the)-258(questions)-258.6(in)-261.5(the)-258(survey)-261(did)-256.9(not)-256.9(differ)-261.2(between)]TJ 0 -1.1174 TD [(the)-246.5(2)-248.8(groups.)-246(H)21.1(o)16.2(w)15.3(e)20.8(v)16.2(e)15(r)16.2(,)-222.3(b)16.2(o)16.2(t)21.8(h)-231.5(t)21.8(h)16.2(e)-226.9(i)16.1(n)16.2(d)21.9(i)16.1(v)16.2(i)16(d)21.9(u)16.2(a)15(l)-225.9(a)20.8(n)16.2(d)-225.7(t)16(o)16.2(t)21.8(a)15(l)-225.9(r)16.2(e)15(s)16.4(p)22(o)16.2(n)16.2(s)22.1(e)15(s)]TJ 0 -1.1116 TD -.0163 Tc [(from)-335.4(al)5.5(l)-340.1(t)5.5(he)-335.3(stud)5.6(y)-339.9(p)5.6(art)5.5(i)-.3(ci)5.5(pant)5.5(s)-339.7(i)5.5(ndicated)-339.9(a)-335.3(st)5.5(ati)5.5(s).1(ticall)5.5(y)-339.9(si)5.5(gni)5.5(-)]TJ T* -.0158 Tc [(can)6.1(t)-397.2(i)6(mpr)6.2(ove)5(men)6.1(t)-397.2(i)6(n)-397(p)6.1(ati)6(e)-.8(nt)-391.4(sa)5(tisf)6.2(act)6(ion)-391.3(f).4(o)6.1(l).2(low)5.3(i).3(ng)-391.3(th)6.1(eir)-391.2(p).4(a)5(r).4(-)]TJ 0 -1.1174 TD -.0166 Tc [(tici)5.2(p)-.4(at)5.2(ion)-328.7(i)-.5(n)-334.5(D)4.5(SME,)]TJ /F9 1 Tf 8.2997 0 TD 0 Tc (P)Tj /F5 1 Tf .766 0 TD (<)Tj /F4 1 Tf .6969 0 TD -.0167 Tc [(0.001)-328.8(\(Table)-330(6\).)]TJ /F3 1 Tf 8.9663 0 0 8.9663 313.0582 504.6235 Tm 0 Tc (Discussion)Tj /F4 1 Tf 9.843 0 0 9.843 323.0361 488.1826 Tm -.0163 Tc [(Ind)5.6(ivi)5.5(dual)5.5(s)-443.4(in)-443.6(bot)5.5(h)-449.4(t)5.5(he)-444.8(usu)5.6(a)-1.3(l)-443.7(c)-1.3(are)-444.8(c)-1.3(o)5.6(n)-.1(tro)5.6(l)-443.7(and)-443.6(t)-.3(elep)5.6(hon)5.6(ic)]TJ -1.0137 -1.1116 TD [(supp)5.5(ort)-299.9(interventio)5.5(n)-305.5(g)-.2(r)5.6(oup)-299.7(showed)-305.5(s)5.7(t)-.3(at)5.4(isti)5.4(cal)5.4(ly)-305.5(si)5.4(gni)5.4(cant)-305.6(a)4.4(nd)]TJ 0 -1.1174 TD -.0166 Tc [(clin)5.3(ically)-167.4(meaning)5.3(ful)-167.6(i)5.2(m)-1.6(p)5.3(rovement)-167.6(in)-167.4(HbA1)5.3(c)-168.6(a)-1.6(ft)5.2(er)-167.4(p)5.3(a)-1.6(rti)5.2(c)-1.6(ip)5.3(ati)5.2(o)-.4(n)]TJ 0 -1.1116 TD -.0164 Tc [(in)-219.1(thi)5.4(s)-218.9(stu)5.5(dy.)-215.7(Thi)5.4(s)-218.9(is)-218.9(impor)5.6(tant)-213.5(because)-214.5(a)-1.4(lth)5.5(oug)5.5(h)-219.1(t)-.3(he)-220.2(s)5.7(t)-.4(ud)5.5(y)-219.1(t)-.3(eam)]TJ T* [(set)-213.4(out)-213.4(to)-219(r)5.7(ecr)5.7(uit)-213.4(t)-.3(ho)5.6(se)-220.1(with)-213.2(an)-213.2(HbA1c)]TJ /F5 1 Tf 14.7218 0 TD 0 Tc (>)Tj /F4 1 Tf .5299 0 TD -.0161 Tc [(8%,)-215.4(i)5.7(n)-218.8(f).1(act)-218.9(t)5.7(he)-214.2(maj)5.7(ori)5.7(ty)]TJ -15.2517 -1.1174 TD -.0166 Tc [(of)-334.4(th)5.3(e)-335.6(i)-.6(nd)5.3(ivi)5.2(duals)-334.3(participatin)5.3(g)-334.5(i)-.5(n)-334.5(t)5.2(his)-334.3(s)-.2(t)5.2(udy)-328.7(were)-329.9(cat)5.2(ego)5.3(r)-.4(ized)]TJ 0 -1.1116 TD -.0163 Tc [(with)-161.4(po)5.6(orly)-161.4(c)-1.3(o)5.6(n)-.1(tr)5.7(olled)-167.1(g)5.6(lycemi)5.5(c)-168.3(s)5.8(tatu)5.6(s)-167(a)4.5(t)-167.3(e)4.5(nrol)5.5(lment)-161.5(\()-.1(eg)5.6(,)-163.7(H)-1(bA1)5.6(c)]TJ /F5 1 Tf T* 0 Tc (>)Tj /F4 1 Tf .5357 0 TD -.0165 Tc [(9%\))5.5(.)-296.4(These)-295.2()-.2(nd)5.4(ings)-293.9(reiterate)-295.2(th)5.4(ose)-295.2(o)-.3(f)-294(o)-.3(th)5.4(ers)]TJ 7.3823 0 0 6.5614 491.8676 415.8424 Tm -.0227 Tc (2,11,12)Tj 9.843 0 0 9.843 515.792 411.4771 Tm -.0169 Tc [(r)5.1(e)-1.9(gardi)4.9(ng)]TJ -20.5967 -1.1116 TD -.0164 Tc [(the)-226(s)0(tat)5.4(i)-.3(st)5.4(ical)5.4(ly)-224.8(sign)5.5(icant)-225(and)-224.8(c)-1.4(li)5.4(nicall)5.4(y)-230.6(m)-1.4(eani)5.4(ngf)5.6(ul)-230.7(b)5.5(e)-1.4(nets)-224.7(o)-.2(f)]TJ 0 -1.1174 TD [(engagin)5.4(g)-259.5(peo)5.4(p)-.3(le)-254.9(with)-253.7(typ)5.4(e)-260.7(2)-259.5(d)-.3(iabet)5.3(e)-1.5(s)-259.3(i)-.4(n)-253.7(D)-1.2(SME.)]TJ 1.0137 -1.1116 TD 0 Tc [(However,)-337.7(the)-338.7(study)-339.5(team)-336.4(found)-333.8(that)-339.9(the)-332.9(addition)-338.7(of)-336.2(tele-)]TJ -1.0137 -1.1116 TD [(phonic)-434.1(engagement)-431.7(concu)-7.8(rrent)-427.2(with)-431.8(DSME)-433.4(did)-429.6(not)-429.6(affect)]TJ 0 -1.1174 TD [(outcomes)-398.2(for)-394.9(people)-395(with)-391.4(diabetes)-398.3(signicantly.)-393.5(There)-400.7(are)]TJ 0 -1.1116 TD [(several)-310.6(factors)-303.6(that)-305.3(may)-299.4(have)-306.2(contributed)-302.8(to)-301.8(the)-304.1(statistically)]TJ T* [(signicant)-330.2(improvements)-323.3(in)-324.9(both)-321.3(groups.)-326.6(The)-322.4(sites)-323.3(selected)]TJ 0 -1.1174 TD [(to)-434.3(participate)-443.5(in)-428.5(this)-436.4(study)-431.7(had)-436.4(to)-434.3(have)-432.9(had)-436.4(a)-434.2(sufciently)]TJ 0 -1.1116 TD [(robust,)-338.2(active,)-342.1(and)-338.5(highquality)-337.4(DSME)-335.5(program)-338.3(to)-336.4(guaran-)]TJ T* [(tee)-293.7(enrollment)-291.4(of)-290.1(study)-287.7(participants.)-291.1(All)-292.4(4)-283.3(FQHCs)-295.9(had)-286.7(level)]TJ ET 62.022 689.556 239.131 .28345 re f 62.022 562.45 239.131 .22675 re f 62.022 670.904 239.131 .22675 re f BT /F7 1 Tf 9.845 0 0 9.845 92.0126 725.1588 Tm (Table)Tj /F4 1 Tf 3.0002 0 TD (5.)Tj /F7 1 Tf 1.2496 0 TD [(Correlation)-335.2(Between)-332.7(Number)]TJ -5.2691 -1.0135 TD [(of)-331.2(Telephonic)-337(Interventions)-332.7(and)-337.8(Achieving)]TJ -.2303 -1.0135 TD [(American)-333.4(Association)-334.8(of)-337(Diabetes)-331(Educators)]TJ 5.7989 -1.0077 TD [(Self-Care)-339(Goal)-332.7(Set)]TJ /F9 1 Tf -7.5955 -1.8427 TD [(Self-care)-335.1(goal)-6833.8(N)]TJ /F4 1 Tf 17.7997 0 TD 4.4754 Tc (rP)Tj -17.7997 -1.9003 TD 0 Tc [(Healthy)-338.7(Eating)-6020.6(169)-3187.4(0.319)]TJ /F5 1 Tf 21.4851 0 TD (<)Tj /F4 1 Tf .5528 0 TD (0.001)Tj -22.0379 -1.0077 TD [(Being)-335.5(Active)-6752.7(127)-3187.4(0.351)]TJ /F5 1 Tf 21.4851 0 TD (<)Tj /F4 1 Tf .5528 0 TD (0.001)Tj -22.0379 -1.0135 TD [(Monitoring)-7595.2(111)-3187.4(0.335)]TJ /F5 1 Tf 21.4851 0 TD (<)Tj /F4 1 Tf .5528 0 TD (0.001)Tj -22.0379 -1.0135 TD [(Taking)-336.7(Medications)-4524.5(92)-3186.5(0.344)-2944.2(0.001)]TJ T* [(Problem)-337.5(Solving)-5811.7(58)-3186.5(0.11)-3444.2(0.411)]TJ 0 -1.0077 TD [(Reducing)-333.9(Risk)-6650.3(89)-3186.5(0.21)-3444.2(0.048)]TJ 0 -1.0135 TD [(Healthy)-338.7(Coping)-6197.5(34)-3186.5(0.379)-2944.2(0.027)]TJ T* [(Total)-335.9(Goals)-335.2(set)-5918.2(680)-3187.4(0.374)]TJ /F5 1 Tf 21.4851 0 TD (<)Tj /F4 1 Tf .5528 0 TD (0.001)Tj -22.0379 -1.0135 TD [(Total)-335.9(Goals)-335.2(Achieved)-3191.1(222)-3187.4(0.428)]TJ /F5 1 Tf 21.4851 0 TD (<)Tj /F4 1 Tf .5528 0 TD (0.001)Tj -22.0379 -1.0077 TD [(%)-336(goals)-334.4(achieved)-4176.2(32.65%)-2399.1(0.458)]TJ /F5 1 Tf 21.4851 0 TD (<)Tj /F4 1 Tf .5528 0 TD (0.001)Tj 8.7511 0 0 8.7511 70.0157 550.6581 Tm [(Correlations)-241.7(between)-236.1(self-care)-246.2(measures)-239.8(and)-237.4(number)-243(of)-242.4(telehealth)]TJ -.9134 -1.0236 TD [(interactions)-402.5(\(inbound)-402.6(and)-399.3(outbound)-404(contacts\).)-398.3(Pearson)-405.6(correlation)]TJ T* [(coefcients,)-526.5(column)]TJ /F9 1 Tf 8.9337 0 TD (r)Tj /F4 1 Tf .9135 0 TD [(in)-521.2(the)-527.6(table)-531.7(above,)-523.9(are)-528.6(used)-526.1(to)-527.6(measure)]TJ -9.8471 -1.0301 TD [(association)-450.1(between)-456.3(the)-449.9(number)-450.3(of)-449.7(telehealth)-454.4(interactions,)-450.5(the)-456.4(N)]TJ 0 -1.0236 TD [(column,)-232.9(and)-237.4(the)-236.1(subject)-236.2(achieving)-236.7(the)-229.6(self-care)-239.7(goal.)-237.6(Each)-233.5(subject)-236.2(in)]TJ T* [(the)-462.9(intervention)-461.3(received)-459.1(telehealth)-460.9(interactions)-467.3(on)-457.6(variable)-463.2(self-)]TJ T* [(care)-334.3(goals)-335.8(\(ie,)-334.5(not)-332.1(all)-332(subjects)-337.1(received)-329.6(all)-338.5(7)-329.2(interventions\).)]TJ .9134 -1.0236 TD [(Correlation)-445.3(also)-447.1(was)-445.3(measured)-448.7(between)-449.9(the)-443.4(entire)-451.4(intervention)]TJ -.9134 -1.0236 TD [(group)-238.9(\(N)]TJ /F5 1 Tf 3.7898 0 TD (=)Tj /F4 1 Tf .7191 0 TD [(222\))-233.6(and)-237.4(3)-238.5(variables:)-244.2(total)-237.7(goals)-238.7(set,)-237.2(total)-237.7(goals)-238.7(achieved,)]TJ -4.5089 -1.0301 TD [(and)-334.6(%)-333.1(o)0(f)-333.1(goals)-329.4(achieved.)]TJ ET 62.022 271.162 490.167 .28342 re f 62.022 86.343 490.167 .22675 re f 189.751 252.283 93.543 .28348 re f 302.853 252.283 93.543 .28348 re f 415.956 252.283 136.233 .28348 re f 62.022 234.595 490.167 .28348 re f BT /F7 1 Tf 9.845 0 0 9.845 211.918 276.8314 Tm (Table)Tj /F4 1 Tf 3.0002 0 TD (6.)Tj /F7 1 Tf 1.2496 0 TD [(Satisfaction)-330.4(Score)-338.6(Comparisons*)]TJ /F9 1 Tf -3.3054 -1.837 TD [(Control)-7476.9(Intervention)]TJ /F4 1 Tf 24.9748 0 TD (P)Tj /F9 1 Tf .8868 0 TD (values)Tj -28.6372 -1.8197 TD [(N)-2403.3(Mean)-2252(SD)-2669(N)-2403.3(Mean)-2251.9(SD)-2248.6(Group)-2389.6(Time)-2390(Interaction)]TJ /F4 1 Tf -13.3944 -1.8946 TD [(Baseline)-340.8(Total)-330.1(Satisfaction)-1990.9(107)-2001.2(26.70)-2005.5(3.05)-1981.5(136)-2001.2(26.73)-2005.5(3.11)-2160(0.548)]TJ /F5 1 Tf 40.5402 0 TD (<)Tj /F4 1 Tf .5528 0 TD [(0.001)-3093.9(0.504)]TJ -41.093 -1.0135 TD [(1-Year)-337.3(Total)-335.9(Satisfaction)-6165.9(28.22)-2005.5(2.52)-5482.7(28.54)-2005.5(2.45)]TJ T* [(Baseline)-340.8(Q1)-7961.1(108)-2502.2(4.46)-2004.6(0.59)-1981.5(136)-2502.2(4.44)-2004.6(0.63)-2160(0.956)]TJ /F5 1 Tf 40.5402 0 TD (<)Tj /F4 1 Tf .5528 0 TD [(0.001)-3093.9(0.580)]TJ -41.093 -1.0077 TD [(1-Year)-337.3(Q1)-12642.8(4.76)-2004.6(0.43)-5983.7(4.79)-2004.6(0.45)]TJ 0 -1.0135 TD [(Baseline)-340.8(Q2)-7961.1(108)-2502.2(4.36)-2004.6(0.57)-1981.5(136)-2502.2(4.43)-2004.6(0.55)-2160(0.142)]TJ /F5 1 Tf 40.5402 0 TD (<)Tj /F4 1 Tf .5528 0 TD [(0.001)-3093.9(0.772)]TJ -41.093 -1.0135 TD [(1-Year)-337.3(Q2)-12642.8(4.62)-2004.6(0.59)-5983.7(4.71)-2004.6(0.52)]TJ T* [(Baseline)-340.8(Q3)-7961.1(108)-2502.2(4.38)-2004.6(0.68)-1981.5(136)-2502.2(4.49)-2004.6(0.56)-2160(0.187)]TJ /F5 1 Tf 40.5402 0 TD (<)Tj /F4 1 Tf .5528 0 TD [(0.001)-3093.9(0.414)]TJ -41.093 -1.0077 TD [(1-Year)-337.3(Q3)-12642.8(4.73)-2004.6(0.45)-5983.7(4.76)-2004.6(0.43)]TJ 0 -1.0135 TD [(Baseline)-340.8(Q4)-7961.1(108)-2502.2(4.39)-2004.6(0.53)-1981.5(136)-2502.2(4.43)-2004.6(0.54)-2160(0.165)]TJ /F5 1 Tf 40.5402 0 TD (<)Tj /F4 1 Tf .5528 0 TD [(0.001)-3093.9(0.418)]TJ -41.093 -1.0135 TD [(1-Year)-337.3(Q4)-12642.8(4.63)-2004.6(0.54)-5983.7(4.74)-2004.6(0.46)]TJ T* [(Baseline)-340.8(Q5)-7961.1(108)-2502.2(4.32)-2004.6(0.67)-1981.5(136)-2502.2(4.24)-2004.6(0.87)-2160(0.946)]TJ /F5 1 Tf 40.5402 0 TD (<)Tj /F4 1 Tf .5528 0 TD [(0.001)-3093.9(0.162)]TJ -41.093 -1.0077 TD [(1-Year)-337.3(Q5)-12642.8(4.69)-2004.6(0.59)-5983.7(4.76)-2004.6(0.51)]TJ 0 -1.0135 TD [(Baseline)-340.8(Q6)-7961.1(107)-2502.2(4.51)-2004.6(0.57)-1981.5(136)-2502.2(4.52)-2004.6(0.61)-2160(0.858)]TJ /F5 1 Tf 40.5402 0 TD (<)Tj /F4 1 Tf .5528 0 TD [(0.001)-3093.9(0.687)]TJ -41.093 -1.0135 TD [(1-Year)-337.3(Q6)-12642.8(4.81)-2004.6(0.39)-5983.7(4.79)-2004.6(0.5)]TJ 8.7511 0 0 8.7511 70.0157 74.4944 Tm [(*Items)-259.5(originally)-268.1(scored)-264.4(on)-263.3(a)-265.6(Likert)-264.9(scale)-266.9(from)-262.1(1)-264.4(\()]TJ /F9 1 Tf 20.3161 0 TD [(strongly)-258.2(agree)]TJ /F4 1 Tf 5.8176 0 TD .2695 Tc [(\)t)269.5(o)7.5(5)5.1(\()]TJ /F9 1 Tf 2.7403 0 TD 0 Tc [(strongly)-264.7(disagree)]TJ /F4 1 Tf 6.9902 0 TD [(\).)-265.7(In)-261.8(order)-264.6(to)-268.5(make)-260.9(higher)-263.6(scores)-269.3(mean)-260.9()54.4(greater)]TJ -36.7777 -1.0236 TD [(agreement,)56.2()-334.3(these)-337(items)-332.1(were)-335.4(reverse)-334.2(scored.)-331.8(Current)-334.7(scores)-334.1(are)-334.3(on)-334.5(a)-330.4(Likert)-336.2(scale)-338.2(from)-326.9(1)-335.7(\()]TJ /F9 1 Tf 37.4579 0 TD [(strongly)-335.9(disagree)]TJ /F4 1 Tf 7.0614 0 TD .3338 Tc [(\)t)333.8(o5)4.6(\()]TJ /F9 1 Tf 2.9477 0 TD 0 Tc [(strongly)-329.5(agree)]TJ /F4 1 Tf 5.8888 0 TD (\).)Tj -52.4423 -1.0236 TD [(Q,)-334.2(quarter;)-331(SD,)-332.8(standard)-332.1(deviation.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 62.022 749.6502 Tm (526)Tj 47.6052 0 TD [(BLUML)-334.7(ET)-338.7(AL.)]TJ ET endstream endobj 50 0 obj <>stream /GS1 gs BT /F4 1 Tf 9.843 0 0 9.843 59.7543 725.1588 Tm 0 0 0 rg 0 Tc 0 Tw [(2)-289.1(o)0(r)-290.2(3)-289.1(recognition)-297(from)-287.8(the)-292.6(National)-288.9(Committee)-292.6(for)-291.2(Quality)]TJ 0 -1.1174 TD [(Assurance)-365.2(\(NCQA\))-367.3(and,)-359.2(in)-359.4(addition,)-365.1(had)-355.8(received)-364.9(accredi-)]TJ 0 -1.1116 TD [(tation)-520.8(status)-514.5(by)-514.8(either)-521.8(AADE)-515.1(or)-520.5(the)-511.4(American)-521.4(Diabetes)]TJ T* [(Association.)-479.5(Accreditation)-481.1(by)-474.5(these)-480.1(organizations)-478.8(ensures)]TJ T* [(compliance)-380(with)-374.2(the)-373.2(National)-381(Standards)-374.8(for)-371.9(Diabetes)-381.9(Self-)]TJ 0 -1.1174 TD [(Management)-559.4(Education)-549.3(and)-551.6(Support.)]TJ 7.3823 0 0 6.5614 215.6031 674.7021 Tm (3)Tj 9.843 0 0 9.843 224.674 670.3369 Tm [(In)-549.3(addition,)-555.2(these)]TJ -16.755 -1.1116 TD [(programs)-258.6(already)-253.2(included)-253.3(a)-249.9(peer)-254.4(support)-255.3(component,)-253.2(which)]TJ T* [(has)-534.2(been)-530.9(suggested)-530.4(to)-526.5(be)-527.5(helpful)-533.2(for)-527.4(improving)-529.7(clinical)]TJ 0 -1.1174 TD [(outcomes)-340.6(of)-330.5(people)-337.4(with)-333.8(type)-334(2)-335.2(diabetes.)]TJ 7.3823 0 0 6.5614 226.2047 641.877 Tm (13)Tj 9.843 0 0 9.843 69.7323 626.5132 Tm [(FQHCs)-514.8(serve)-508.7(economically)-514.8(disadvantaged)-514.4(populations.)]TJ -1.0137 -1.1116 TD [(They)-289(also)-282(commonly)-283.3(use)-286.5(the)-281.1(patient-centered)-290(model)-284.5(of)-284.4(care)]TJ 0 -1.1174 TD [(delivery,)-308.5(have)-312(an)-302.9(appearance)-311.7(of)-307.4(patient)-309.9(loyalty,)-306.4(and)-304(at)-308.8(least)]TJ 0 -1.1116 TD [(with)-235.9(those)-237(attaining)-237.4(level)-238.5(3)-231.5(NCQA)-238.4(recognition,)-237.1(show)-235.5(greater)]TJ T* [(improvement)-454.9(across)-446.2(a)-445.8(number)-446.7(of)-445.7(outcomes.)]TJ 7.3823 0 0 6.5614 242.0787 587.0549 Tm (14)Tj 9.843 0 0 9.843 253.8708 582.6896 Tm [(This)-449(might)]TJ -19.7212 -1.1116 TD [(suggest)-452.1(that)-443.6(patients)-449.1(cared)-452.5(for)-441(in)-445.8(such)-448.9(settings)-447.7(might)-444.7(not)]TJ 0 -1.1174 TD [(benet)-354.5(from)-345.4(the)-350.2(addition)-350.2(of)-347.7(support.)-350.9(The)-345.5(time)-352.6(frame)-348.8(of)-347.7(18)]TJ 0 -1.1116 TD [(months)-428.2(may)-426.2(have)-427.2(been)-427.2(too)-423.9(short)-425.9(to)-428.5(result)-428.3(in)-422.8(a)-428.5(change)-424.8(in)]TJ T* (outcomes.)Tj 7.3823 0 0 6.5614 100.063 543.2313 Tm (13)Tj 9.843 0 0 9.843 69.7323 527.8676 Tm [(It)-313.3(is)-313.2(important)-312.2(to)-307.6(note)-316.7(that)-311.1(those)-311.9(receiving)-313.1(the)-315.6(telephonic)]TJ -1.0137 -1.1116 TD [(support)-491.4(did)-487.2(have)-490.5(a)-491.8(signicantly)-488(greater)-495.1(number)-487(of)-491.7(visits)]TJ T* [(\(Table)-344.3(3\).)-339.7(The)-339.7(study)-339.5(team)-342.1(interprets)-347.5(this)-338.5(to)-342.1(mean)-342(that)-339.9(tele-)]TJ 0 -1.1174 TD [(phonic)-324.7(support)-318.6(reinforced)-319.8(the)-321.4(importance)-321.2(of)-319(obtaining)-322.5(risk-)]TJ 0 -1.1116 TD [(reducing)-339.5(care.)]TJ 1.0137 -1.1116 TD -.0164 Tc [(Qu)5.5(alit)5.4(ati)5.4(v)-.2(e)-439.1(i)5.4(nsig)5.5(ht)-432.3(gleaned)-432.2(fro)5.5(m)-439.2(s)5.7(tudy)-432.2(participant)-438.1(d)5.5(iscu)5.5(s-)]TJ -1.0137 -1.1174 TD -.0162 Tc [(sion)5.7(s)-253.2(w)-.9(ith)-253.4(t)5.6(h)0(ei)5.6(r)-259.2(d)5.7(iab)5.7(e)-1.2(tes)-259(e)4.6(ducato)5.7(r)0(s)-253.2(w)-.9(as)-253.2(th)5.7(at)-253.6(tho)5.7(s).2(e)-254.6(r)0(eceiv)5.7(i)-.1(ng)-253.4(t)5.6(h)0(e)]TJ 0 -1.1116 TD -.016 Tc [(tel)5.8(e)-1(pho)5.9(nic)-289(s).4(up)5.9(port)-287.9(wer)6(e)-294.7(ap)5.9(preciat)5.8(ive)-289(o).2(f)-293.5(t)5.8(he)-294.7(su)5.9(ppo)5.9(rt.)-290.1(T)-1(h)5.9(i).1(s)-293.4(m)4.7(ay)]TJ T* -.0164 Tc [(sugg)5.5(est)-311.4(t)-.3(h)5.5(a)-1.4(t)-311.4(t)-.3(elep)5.5(hon)5.5(ic)-312.4(sup)5.5(port)-311.4(o)5.5(f)-311.2(this)-311(t)5.4(ype)-312.4(may)-311.2(b)-.2(e)-312.4(e)4.4(special)5.4(l)-.4(y)]TJ T* -.0157 Tc [(imp)6.2(orta)5.1(n).5(t)-425.9(i)6.1(n)-425.7(c)-.7(a)5.1(s).7(es)-419.8(whe)5.1(n)-425.7(ind)6.2(i).4(vi)6.1(dua)5.1(ls)-425.5(cy)6.2(cle)-421.1(b).5(et)6.1(wee)5.1(n)-425.7(co)6.2(nte)5.1(m)-.7(-)]TJ 0 -1.1174 TD -.0165 Tc [(plating)-265.3(a)-1.5(n)5.4(d)-271(pr)5.5(eparing)-265.3(t)-.4(o)-265.3(i)-.4(ncorp)5.4(orat)5.3(e)-272.2(l)5.3(i)-.4(fes)5.6(t)-.4(yle)-266.4(c)-1.5(h)5.4(a)-1.5(ng)5.4(es.)]TJ 7.3823 0 0 6.5614 265.4361 422.6456 Tm -.023 Tc (14,15)Tj 9.843 0 0 9.843 283.8614 418.2802 Tm -.0185 Tc (The)Tj -22.7681 -1.1116 TD -.0165 Tc [(mod)5.4(e)-1.5(l)-288.4(o)-.3(f)-288.3(pro)5.4(vid)5.4(i)-.4(ng)-288.3(telep)5.4(hon)5.4(ic)-289.5(sup)5.4(port)-288.4(us)5.6(ing)-288.3(a)-289.5(centr)5.5(a)-1.5(lized)-288.3(c)-1.5(all)]TJ T* -.016 Tc [(cen)5.9(ter)-443.3(a)-1(s)-443.1(a)-1(n)-443.3(a)-1(p)5.9(pro)5.9(ach)-443.3(to)-443.3(helpi)5.8(n).2(g)-443.3(i).1(nd)5.9(ivi)5.8(dual)5.8(s)-448.9(g)5.9(e)-1(t)-443.4(t).1(o)-443.3(a)-444.5(poi)5.8(nt)]TJ 0 -1.1174 TD -.0168 Tc [(where)-410.7(t)-.7(h)5.1(e)-1.8(y)-409.6(a)4(re)-410.7(r)5.2(ead)5.1(y)-409.6(t)-.7(o)-409.6(e)4(ngage)-410.7(i)5(n)-409.6(sel)5(f-care)-405(i)-.7(s)-409.4(a)-410.7(model)-409.7(t)-.7(h)5.1(a)-1.8(t)]TJ 0 -1.1116 TD -.0166 Tc [(shou)5.3(ld)-334.5(b)5.3(e)-335.6(expl)5.2(ored)-328.7(fur)5.4(ther.)]TJ 1.0137 -1.1116 TD 0 Tc [(Many)-236.9(in)-232.7(the)-235(intervention)-240.7(group)-230.1(commented)-240.6(that)-236.2(they)-236.1(were)]TJ -1.0137 -1.1174 TD [(sad)-378.6(that)-368.7(the)-379(telephonic)-372(support)-376.2(had)-373.1(to)-370.9(end.)-376.5(The)-374.3(telephonic)]TJ 0 -1.1116 TD [(support)-272.6(provided)-269.3(in)-267.3(this)-269.4(study)-270.4(was)-270.1(concurrent)-273.8(with)-270.5(at)-268.4(least)-272.8(a)]TJ T* [(portion)-307.4(of)-307.4(the)-304.1(DSME)-306.7(participation)-306.4(of)-307.4(study)-304.9(participants.)-308.4(As)]TJ T* [(a)-370.9(chronic)-373(disease,)-371.5(managing)-369.6(type)-368.6(2)-369.7(diabetes)-369.5(is)-370.8(an)-366.2(ongoing)]TJ 0 -1.1174 TD [(process.)-519.9(Telephonic)-517.1(support)-520.2(is)-514.7(an)-516(opportunity)-513.6(to)-514.9(engage)]TJ 0 -1.1116 TD [(with)-403(the)-402(person)-399.2(with)-403(diabetes)-404(as)-400.6(a)-399.7(way)-402.8(to)-399.7(enable)-401.9(them)-398.6(to)]TJ T* [(succeed)-305.9(with)-299.3(their)-294.9(goals)-300.3(and)-298.2(identify)-298.3(and)-298.2(solve)-300.3(problems)-299.1(as)]TJ 0 -1.1174 TD [(they)-374.3(encounter)-382.1(challenges.)-376.3(All)-373.1(4)-375.5(FQHCs)-376.6(are)-374.2(continuing)-375.4(to)]TJ 0 -1.1116 TD [(support)-664.2(their)-669.3(patients)-662.2(with)-667.9(diabetes)-663.2(through)-664.4(telephone,)]TJ T* [(email,)-433.2(or)-434.1(texting)-429.7(after)-434.1(the)-430.8(study,)-435.1(indicating)-428.6(that)-432(they)-431.9(saw)]TJ 0 -1.1174 TD [(value)-336.3(in)-336.4(this)-332.8(intervention.)]TJ 1.0137 -1.1116 TD [(The)-420.4(AADE)-422.9(accreditation)-423.8(principles)-416.7(utilized)-420.6(in)-422.8(this)-419.2(ran-)]TJ -1.0137 -1.1116 TD [(domized,)-412.3(controlled)-411.1(evaluation)-412.3(contributed)-412.2(to)-405.5(the)-407.8(delivery)]TJ 0 -1.1174 TD [(of)-393.8(comprehensive)-394.5(face-to-face)-400.3(care)-393.8(with)-391.4(consistent)-393.5(assess-)]TJ 0 -1.1116 TD [(ment)-415.9(and)-413.4(documentation)-416.9(over)-414.5(time.)-413.7(The)-408.8(4)-415.8(FQHCs)-411.1(in)-411.3(this)]TJ T* [(study)-500.8(executed)-503.2(these)-497.3(principles)-503.1(effectively)-506.7(with)-495.1(resultant)]TJ T* [(improvement)-299.4(in)-296.1(glycemic)-301.8(status)-295.6(in)-296.1(a)-296(large)-295.9(group)-293.5(of)-295.9(patients)]TJ 0 -1.1174 TD [(with)-235.9(an)-233.7(average)-242.7(HbA1c)]TJ /F5 1 Tf 9.6763 0 TD (>)Tj /F4 1 Tf .5529 0 TD [(10)-232.6(at)-233.9(enrollment.)-237.2(Results)-240.2(show)-235.5(that)]TJ -10.2292 -1.1116 TD [(this)-367.3(patient-centered,)-374.1(team-based)-373.9(care)-370.7(effectively)-368.4(produced)]TJ T* [(statistically)-421.5(signicant)-422.3(and)-419.2(clinically)-418.3(meaningful)-418(improve-)]TJ 0 -1.1174 TD [(ment)-444.7(for)-441(all)-442.5(participating)-444.6(patients,)-441(with)-443.3(12-month)-442.1(HbA1c)]TJ 0 -1.1116 TD [(reductions)-635.4(of)-624.2(1.7)-627.7(and)-632.3(1.4)-621.9(for)-631(intervention)-632.3(and)-626.5(control)]TJ T* [(groups,)-315.1(respectively.)-321(Diabetes)-318.5(is)-313.2(a)-313.3(chronic)-321.2(condition)-311(and)-315.5(as)]TJ 0 -1.1174 TD [(such)-276.1(requires)-281.7(ongoing)-272.8(engagement.)-279.7(There)-279.7(remains)-276.1(a)-273(need)-277.4(to)]TJ 0 -1.1116 TD [(identify)-620.9(additional)-624.4(avenues)-621.5(to)-612.9(provid)-6.7(e)-612.8(support,)-621.6(perhaps)]TJ T* [(through)-370.7(innovative)-376.6(involvement)-373.2(with)-368.4(diabetes)-375.2(educators)-370.4(to)]TJ 0 -1.1174 TD [(address)-487.7(unmet)-486.1(needs,)]TJ 7.3823 0 0 6.5614 148.4787 72 Tm (15)Tj 9.843 0 0 9.843 160.611 67.5779 Tm [(improved)-489.4(engagement)-483.6(with)-489.4(peers)]TJ -10.2465 -1.1116 TD [(through)-330.4(social)-331.5(media,)]TJ 7.3823 0 0 6.5614 146.6078 61.0016 Tm (16,17)Tj 9.843 0 0 9.843 166.4503 56.6362 Tm [(or)-324.7(novel)-329.3(touchpoints)-330.3(to)-324.9(reinforce)]TJ 14.67 67.9184 TD [(messaging)-439.4(through)-434(either)-441.1(previously)-438.4(untapped)-437.5(health)-435.4(care)]TJ 0 -1.1174 TD [(or)-330.5(community)-336.3(settings.)]TJ 1.0137 -1.1116 TD [(T)15(h)0(i)20.7(s)-766.9(r)16.2(a)0(n)19.7(d)16.2(om)19.6(iz)25.3(ed)19.7(,)-763.7(c)0(o)19.7(n)16.2(tr)20.7(ol)26.5(le)19.6(d)-767.1(s)16.4(tu)20.7(dy)-751(de)19.7(m)15(o)0(n)20.8(s)0(t)20.9(r)16.2(at)19.6(e)15(d)-767.1(th)20.7(a)15(t)]TJ -1.0137 -1.1116 TD [(c)15(o)0(m)19.6(p)0(r)26.6(e)0(h)19.7(e)15(ns)21(iv)20.7(e)-411.2(f)0(a)25.5(c)0(e)18.5(-)0(t)26.5(o)0(-)20.9(f)0(a)25.5(c)0(e)-401.9(c)0(a)18.5(r)0(e)-400.7(w)0(i)25.6(t)0(h)-399.7(c)0(o)19.7(n)0(s)26.8(i)0(s)20.9(t)0(e)19.6(n)16.2(t)-415.9(a)15(ss)21.2(es)19.9(s)16.4(m)0(e)18.4(n)16.2(t)]TJ T* [(a)15(n)0(d)-365.1(d)16.2(oc)19.7(um)25.4(en)19.7(t)16.1(a)0(t)19.5(i)0(o)26.5(n)-375.5(o)16.2(v)0(e)19.7(r)-369.7(ti)20.6(m)15(e)-376.6(p)16.2(r)0(o)20.9(d)0(u)26.6(c)0(e)18.5(d)-369.7(si)20.9(gn)26.6(i)20.9(c)15(a)0(n)19.7(t)-369.8(im)19.5(p)16.2(r)0(o)20.9(v)0(e)25.4(-)]TJ 0 -1.1174 TD [(m)15(e)0(n)19.7(t)-485(fo)20.9(r)-484.9(p)0(e)25.4(o)0(p)20.8(l)0(e)-475.8(w)0(i)25.6(t)0(h)-480.4(d)16.2(ia)19.6(b)16.2(e)0(t)19.5(e)0(s)25.6(.)-487.2(Th)19.6(e)-486.1(a)0(d)25.4(d)0(i)20.7(t)0(i)26.3(o)0(n)-480.3(o)16.2(f)-490.6(s)16.4(tr)20.8(uc)25.4(tu)20.7(re)25.5(d)]TJ 0 -1.1116 TD [(te)25.3(le)19.6(p)16.2(h)0(o)20.8(n)0(i)26.5(c)-353.6(su)21(p)16.2(p)0(o)20.8(r)0(t)-336.4(o)0(v)20.8(e)15(rl)20.7(ap)25.4(pi)20.7(ng)-336.3(in)-336.4(ti)20.6(me)-338.7(wi)19.8(t)16.1(h)-352.4(th)26.5(e)-353.6(c)0(o)25.4(m)0(p)19.6(r)0(e)25.5(h)0(e)19.7(n)16.2(-)]TJ T* [(si)26.7(ve)-239.5(fa)19.7(c)15(e)0(-)19.7(t)0(o)26.5(-)0(f)20.9(a)0(c)24.3(e)-249.9(pr)20.9(ov)26.6(is)20.9(io)20.7(n)-248.8(o)16.2(f)-254.5(c)15(ar)19.7(e)-249.9(i)16.1(n)-254.5(t)16.1(hi)20.7(s)-248.6(e)0(n)25.4(v)0(i)20.7(r)0(o)20.9(n)16.2(me)18.4(n)16.2(t)-248.9(di)20.7(d)-248.8(n)0(o)26.6(t)]TJ 0 -1.1174 TD [(pr)26.6(od)20.8(uc)25.4(e)-526.4(s)0(t)20.9(a)15(ti)20.6(st)26.7(ic)19.6(al)25.3(ly)-514.9(si)26.7(gn)20.8(i)26.6(ca)18.5(nt)-509.2(cl)19.5(in)26.5(ic)19.6(al)-510.3(or)-514.8(be)25.4(ha)19.7(vi)26.5(or)20.9(al)-510.3(ca)18.5(re)]TJ 0 -1.1116 TD [(im)25.2(pr)20.9(o)16.2(v)0(e)19.7(m)15(en)19.7(t.)-396.3(It)-394(is)-399.6(w)15.3(o)0(r)20.9(t)0(h)-394(n)0(o)20.8(t)16.1(in)20.7(g)-404.3(t)0(h)20.7(a)0(t)-395.1(t)0(h)20.7(e)-405.4(pr)20.9(o)16.2(f)0(e)19.7(s)0(s)21.2(i)16(on)20.8(al)25.3(s)-409.8(w)0(h)25.7(o)]TJ T* [(w)15.3(o)0(r)20.9(k)-300.6(wi)19.8(t)16.1(h)-306.4(t)16.1(h)0(e)-291.3(p)0(e)19.7(o)16.2(pl)20.7(e)-301.8(w)0(i)19.8(t)16.1(h)-300.6(d)0(i)20.7(a)0(b)25.4(e)0(t)19.5(e)0(s)-291.2(f)0(o)26.6(u)0(n)20.8(d)-300.6(va)25.4(lu)20.7(e)-301.8(i)0(n)-290.3(t)0(h)26.5(e)-307.5(a)15(d)0(d)20.8(e)0(d)]TJ 0 -1.1174 TD [(co)13.9(nn)20.8(ec)12.8(ti)14.8(on)15.1(.)-251.1(P)0(e)14.1(r)0(h)15.1(a)0(p)13.9(s)-248.6(te)13.8(le)13.8(ph)20.8(on)15.1(ic)-245.4(su)15.3(pp)15.1(or)15.1(t)-248.9(i)0(n)-244.2(s)0(e)14.1(t)0(t)14.8(i)0(n)15(g)0(s)-238.2(t)0(h)14.9(a)0(t)-245.4(d)0(o)-244.1(n)0(o)20.8(t)]TJ 0 -1.1116 TD [(of)15.1(fe)14(r)-335.1(c)0(o)19.7(m)0(p)13.9(r)0(e)14(h)0(e)13.9(n)0(s)15.3(i)0(v)15(e)-336.3(DS)14.4(ME)-326.8(wo)14.2(ul)20.7(d)-335.2(h)0(e)13.9(l)0(p)-330.6(m)0(a)18.4(i)0(n)15(t)0(a)13.8(i)0(n)-324.9(c)0(o)13.9(n)0(t)14.9(i)0(n)15(u)0(i)15(t)0(y)]TJ T* [(of)-238.3(ca)12.8(re)-239.5(wi)19.8(th)-238.5(th)15(ei)13.8(r)-248.7(p)0(e)13.9(o)0(p)20.8(l)0(e)-239.6(w)0(i)14.1(t)0(h)-238.5(d)0(i)14.9(a)0(b)13.9(e)0(t)13.8(e)0(s)14.1(.)-245.3(Th)13.9(is)-238.3(co)19.7(ul)14.9(d)-248.8(a)0(p)13.9(p)0(l)14.9(y)-243(bo)15.1(th)]TJ T* [(within)-457.1(FQHCs)-463(and)-453.7(other)-461.8(health)-458.4(care)-462.9(settin)-8(gs.)-454.7(Furthe)-7.7(r)-450.3(re-)]TJ 0 -1.1174 TD [(search)-464.9(and)-459.5(explor)-7.9(ation)-461.9(of)-457.2(mean)-8(s)-455.9(t)0(o)-457.3(enhan)-7.8(ce)-459.5(DSMES)-457.4(are)]TJ 0 -1.1116 TD [(neede)-9(d)-248.8(t)0(o)-250(advan)-7.8(ce)-257.9(the)-252.3(unders)-7.5(tandin)-8(g)-248.8(o)0(f)-255.6(approa)-8.9(ches)-254.2(that)-253.5(will)]TJ T* [(advan)-7.8(ce)-332.8(care.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 310.8472 504.5668 Tm (Acknowledgement)Tj /F4 1 Tf 9.843 0 0 9.843 320.8251 488.1259 Tm [(The)-241.8(authors)-244.9(would)-242.7(like)-247.7(to)-238.5(thank)-242.9(the)-246.5(study)-241.6(participants,)-250.8(the)]TJ -1.0137 -1.1174 TD [(staff)-415.5(at)-418.2(Diabetes)-422.2(Self-Management)-421.9(Education)-422.6(programs)-419.9(at)]TJ 0 -1.1116 TD [(El)-481.6(Rio)-488.3(Community)-480.2(Healt)-9(h)-479.1(Center,)-485.8(Missouri)-487.6(Cross)-484.2(Trails)]TJ T* [(Medical)-404(Center,)-399.4(North)-403.9(Carolina)-404.1(Triad)-399.6(Adult)-404.1(and)-401.9(Pediatric)]TJ T* [(Medicine,)-391.3(Inc.,)-391.4(West)-387.9(Virginia)-391.3(Family)-389.2(Care)-393.6(Health)-390.2(Center,)]TJ 0 -1.1174 TD [(and)-563.2(at)-562.2(the)-563.3(National)-565.3(Center)-568.8(for)-561.9(Farmworker)-568.1(Health)-563(call)]TJ 0 -1.1116 TD [(center)-459.4(for)-458.3(their)-456.2(invaluable)-464.2(contribution)-458.4(to)-457.3(this)-459.5(and)-453.7(future)]TJ T* [(projects.)-538.7(We)-541.3(would)-536.4(also)-535.4(like)-541.5(to)-538(thank)-536.7(AADE)-538.1(staff)-542.2(and)]TJ 0 -1.1174 TD [(member)-403(volunteers)-405(for)-400.7(their)-404.3(help)-403.1(with)-403(the)-402(design)-405.1(and)-401.9(im-)]TJ 0 -1.1116 TD [(plementation)-502.3(of)-497.5(this)-499.8(project;)-501.1(and)-499.8(Sandra)-504.1(Leal)-497.6(and)-499.8(Kelly)]TJ T* [(Boesen)-280.5(for)-279.7(conducting)-284.3(the)-281.1(health)-279.9(navigator)-283.2(training.)-284.5(We)-282.1(are)]TJ 0 -1.1174 TD [(grateful)-385.7(to)-382.5(the)-379(American)-388.9(Pharmacists)-385.1(Association)-383.9(Founda-)]TJ 0 -1.1116 TD [(tion)-419.4(for)-417.9(their)-421.6(willingness)-423.2(to)-417(modify)-422.6(the)-419.3(Project)-424.8(IMPACT:)]TJ T* [(Diabetes)-301.2(database)-301.4(system)-302.5(to)-296.1(accommodate)-308.5(the)-298.3(needs)-295.6(of)-301.7(this)]TJ T* [(project,)-313.2(and)-309.7(the)-309.9(work)-310.5(of)-307.4(our)-308.5(colleagues)-315.2(at)-308.8(the)-315.6(University)-312.7(of)]TJ 0 -1.1174 TD [(Kansas)-268.6(for)-262.4(their)-266.1(efforts)-267.9(to)-261.5(unify)-264.8(the)-269.5(work)-264.4(of)-261.4(all)-269.7(the)-263.8(Together)]TJ 0 -1.1116 TD [(on)-336.3(Diabetes)-347.3(grantees.)-343.9(This)-339.6(work)-345.1(would)-340.6(not)-337.5(have)-346.6(been)-340.8(pos-)]TJ T* [(sible)-254.4(without)-256.6(the)-258(encouragement)-263.4(and)-252.1(vision)-260.1(of)-249.8(Patti)-260.3(Doykos.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 310.8472 269.518 Tm [(Author)-332.4(Disclosure)-336.7(Statement)]TJ /F4 1 Tf 9.843 0 0 9.843 320.8251 253.0771 Tm [(The)-293.6(authors)-302.5(declare)-300.4(that)-299.6(there)-301.7(are)-299.3(no)-295.9(conicts)-299(of)-295.9(interest.)]TJ -1.0137 -1.1116 TD [(This)-374.2(study)-374.1(was)-379.5(funded)-376.4(by)-376.6(a)-370.9(grant)-381.1(from)-374.2(The)-374.3(Bristol-Myers)]TJ 0 -1.1174 TD [(Squibb)-265.8(Foundation)-265.7(to)-261.5(the)-269.5(American)-267.9(Association)-268.7(of)-267.1(Diabetes)]TJ 0 -1.1116 TD [(Educators)-335.9(as)-337.2(part)-334(of)-330.5(their)-335.2(Together)-335(on)-336.3(Diabetes)-335.8(program.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 310.8472 187.7102 Tm (References)Tj /F4 1 Tf 9.2951 0 0 9.2951 315.496 171.6094 Tm [(1.)-500.4(American)-248.4(Association)-246(of)-246.6(Diabetes)-245.1(Educators.)-250.4(AADE7)-245.2(Self-)]TJ 1.2503 -1.1223 TD [(Care)-766.3(Behaviors)]TJ /F5 1 Tf 6.7214 0 TD ()Tj /F4 1 Tf .8844 0 TD [(:)-762(American)-766.9(Association)-770.5(of)-765(Diabetes)]TJ -7.6057 -1.1284 TD [(Educators)-354(\(AADE\))-359.8(Position)-355.2(Statement.)-362.4(2011.)-354.4(https://www)]TJ 0 -1.1223 TD [(.diabetese)8.2(ducator.org/)10.8(docs/default-)7.9(source/practice)7.1(/practice-)]TJ 0 -1.1284 TD .0202 Tc [(re)3.7(sources/position-s)2.7(t)-3.8(atements)]TJ 12.4424 0 TD .0205 Tc [(/aade7-self-care)4(-)-.3(behaviors)3(-)]TJ -12.4424 -1.1223 TD -.0187 Tc [(p)5.6(o)-.5(siti)6.1(on-statement)24.4(.pdf?sfvrsn=6)-275(A)4(cces)6.4(s).3(ed)-268.9(No)5.6(vember)-271.2(4,)-274.9(2)5.6(018)5.6(.)]TJ -1.2503 -1.1284 TD 0 Tc [(2.)-500.4(Powers)-401.3(MA,)-409.9(Bardsley)-405.6(J,)-401.9(Cypress)-407(M,)-402(et)-406.5(al.)-406.5(Diabetes)-403.7(self-)]TJ 1.2503 -1.1223 TD [(management)-431.6(education)-439.7(and)-431.6(support)-428.8(in)-432.8(type)-437.3(2)-427.1(diabetes:)-438.3(a)]TJ 0 -1.1284 TD [(joint)-456.4(position)-456(statement)-462.2(of)-453.9(the)-455.4(American)-461.9(Diabetes)-458.6(Asso-)]TJ 0 -1.1223 TD [(ciation,)-410.3(the)-412.7(American)-413.1(Association)-416.7(of)-411.3(Diabetes)-415.9(Educators,)]TJ 0 -1.1284 TD [(and)-260.8(the)-266.3(Academy)-264.9(of)-264.9(Nutrition)-259.1(and)-266.9(Dietetics.)-268.6(Diabetes)-263.4(Educ)]TJ 0 -1.1223 TD (2015;41:417430.)Tj /F3 1 Tf 8.9663 0 0 8.9663 59.7543 749.7069 Tm [(AUGMENTED)-339.9(DIABETES)-340.1(SELF-MANAGEMENT)-338.1(SUPPORT)-25527.3(527)]TJ ET endstream endobj 58 0 obj <>stream /GS1 gs BT /F4 1 Tf 9.2951 0 0 9.2951 66.6708 725.1588 Tm 0 0 0 rg 0 Tc 0 Tw [(3.)-500.4(Beck)-416.3(J,)-414.1(Greenwood)-411.6(DA,)-418.3(Blanton)-411.4(L,)-416.9(et)-412.6(al.)-412.6(2017)-415.3(National)]TJ 1.2503 -1.1223 TD [(standards)-698.9(for)-688.2(diabetes)-701(self-management)-695.9(education)-695.9(and)]TJ 0 -1.1284 TD [(support.)-331.3(Diabetes)-342.7(Educ)-329.9(2018;44:3550.)]TJ -1.2503 -1.1223 TD [(4.)-500.4(Li)22.8(t)12.6(c)0(h)19.9(m)12.5(a)14(n)-244.1(M)12.8(L)0(,)-233.9(R)13.4(ot)24.7(hw)22.5(el)20.5(l)-243.5(E)16.3(,)-244(E)0(d)22.2(e)14(lm)19(a)14(n)-244.1(LS)25.4(.)-244(T)0(h)22.2(e)-242.2(di)24.7(ab)19.9(e)14(t)12.6(es)-235.4(on)24.1(l)12.6(i)12.6(n)0(e)]TJ 1.2503 -1.1283 TD [(c)14(o)0(m)18.4(m)12.5(un)24.1(i)12.6(t)12.6(y)0(:)-420.6(o)0(l)18.6(d)0(e)26(r)-435.5(a)14(d)0(u)24.1(l)12.6(ts)-425.8(s)12.9(u)0(p)24.1(p)0(o)24.1(r)0(t)22.4(i)12.6(ng)-421.1(se)20.8(l)12.6(f)0(-)19.5(c)14(ar)23.7(e)-437.4(t)12.6(hr)21.8(ou)24.1(gh)-421.1(pe)26(er)]TJ 0 -1.1223 TD [(he)26(al)20.5(t)12.6(h)0(.)-311.3(P)15.3(at)20.5(i)12.6(e)0(n)19.9(t)-316.7(Ed)22.2(uc)-309.5(Co)19.3(un)24.1(s)-322.5(2)0(0)24.1(1)0(8)24.1(;)12.6(10)24.1(1:)24.7(51)24.1(8)24.1(52)24.1(3.)]TJ -1.2503 -1.1284 TD [(5.)-500.4(Trump)-388.8(LJ,)-385.6(Mendenhall)-390.3(TJ.)-385.6(Community)-388.3(health)-386.3(workers)-394.8(in)]TJ 1.2503 -1.1223 TD [(diabetes)-243.5(care:)-240.8(a)-236.1(systematic)-241.9(review)-238.3(of)-240.5(randomized)-241.1(controlled)]TJ 0 -1.1284 TD [(trials.)-334.2(Fam)-336.5(Syst)-331.4(Health)-339.1(2017;35:320340.)]TJ -1.2503 -1.1223 TD [(6.)-500.4(Horny)-370.6(M,)-371.5(Glover)-368.3(W,)-370.5(Gupte)-371.9(G,)-367.7(Saraswat)-372.9(A,)-373.8(Vimalananda)]TJ 1.2503 -1.1284 TD [(V,)-434.8(Rosenzweig)-433.7(J.)-432.4(Patient)-437.6(navigation)-435.1(to)-432.8(improve)-433.5(diabetes)]TJ 0 -1.1223 TD [(outpatient)-349.1(care)-351(at)-345.5(a)-345.9(safety-net)-352.1(hospital:)-343.9(a)-345.9(retrospective)-356.2(co-)]TJ 0 -1.1284 TD [(hort)-331.7(study.)-334.8(BMC)-338.6(Health)-333(Serv)-333.3(Res)-337.9(2017;17:759.)]TJ -1.2503 -1.1284 TD [(7.)-500.4(NCQA.)-266.3(Comprehensive)-269.8(Diabetes)-263.4(Care)-266.2(\(CDC\).)-266.7(2017.)-262.9(http://)]TJ 1.2503 -1.1223 TD [(ww)21(w)22.7(.)0(n)18.1(c)14(qa)32.1(.o)18.1(rg)21.8(/)12.6(r)0(e)23.7(p)0(o)18(r)0(t)22.4(-)0(c)23.7(a)0(r)17.6(d)0(s)18.9(/)12.6(he)19.9(a)14(l)0(t)19.2(h)0(-)21.8(p)0(l)24.7(a)0(n)19.9(s)0(/)19.5(s)12.9(ta)20.5(te)20.5(-o)21.8(f-)19.5(he)19.9(a)14(l)0(t)19.2(h)0(-)21.8(c)0(a)21.8(r)0(e)17.6(-)]TJ 0 -1.1284 TD -.0178 Tc (quality/2017-table-of-contents/d)Tj 12.4119 0 TD -.0175 Tc [(iabet)-4.9(e)2.6(s-care)-271.9(Accessed)-267.7(A)-.9(ugus)-4.6(t)]TJ -12.4119 -1.1223 TD -.0182 Tc [(15,)-335.4(2018.)]TJ -1.2503 -1.1284 TD 0 Tc [(8.)-500.4(Zissimopoulos)-480.8(J,)-481.2(Joyce)-477.9(GF,)-480.6(Scarpati)-481.4(LM,)-477.3(Goldman)-481.5(DP.)]TJ 1.2503 -1.1223 TD [(Did)-282(Medicare)-287.4(Part)-283.9(D)-282.3(reduce)-284.2(disparities?)-287.1(Am)-282(J)-285.9(Manag)-282.9(Care)]TJ 0 -1.1284 TD (2015;21:119128.)Tj -1.2503 -1.1223 TD [(9.)-500.4(Watson)-465.4(LL,)-467.7(Bluml)-461.4(BM.)-467.9(Integrating)-464.3(pharmacists)-470.6(into)-463(di-)]TJ 1.2503 -1.1284 TD [(verse)-571.7(diabetes)-579(care)-576.6(teams:)-574(implementation)-578.2(tactics)-572.2(from)]TJ 0 -1.1223 TD [(Project)-531.9(IMPACT:)-537.7(Diabetes.)-531.8(J)-529.9(A)0(m)-532.1(Pharm)-534.2(Assoc)-529.3(\(2003\))]TJ 0 -1.1284 TD (2014;54:538541.)Tj -1.7505 -1.1223 TD [(10.)-500.5(Bluml)-321.1(BM,)-321.6(Watson)-319(LL,)-321.3(Skelton)-324.1(JB,)-321.4(Manolakis)-324.1(PG,)-315.9(Brock)]TJ 1.7505 -1.1284 TD [(KA.)-442.7(Improving)-438(outcomes)-446.8(for)-438.1(diverse)-443.3(populations)-442.3(dispro-)]TJ 0 -1.1223 TD [(portionately)-467.6(affected)-467.3(by)-457.7(diabetes:)-468.8(nal)-464.6(results)-462.1(of)-460(Project)]TJ 0 -1.1284 TD [(IMPACT:)-427.9(Diabetes.)-434.2(J)-426.2(A)0(m)-434.5(Pharm)-424.5(Assoc)-431.7(\(2003\))-432.5(2014;54:)]TJ 0 -1.1223 TD (477485.)Tj -1.7505 -1.1284 TD [(11.)-500.5(Fe)23.1(rg)21.8(us)25(on)-537(S,)-539.8(S)15.3(w)0(a)18.3(n)-549.1(M)12.8(,)-549(Sm)21.7(al)20.5(do)24.1(ne)-535.1(A.)-544.6(D)16.6(o)0(e)19.9(s)-548.2(di)24.7(ab)19.9(e)14(t)0(e)20.5(s)-548.2(se)20.8(l)12.6(f)0(-)]TJ 1.7505 -1.1223 TD [(m)12.5(a)0(n)19.9(a)14(ge)19.9(m)12.5(e)14(nt)-530.3(ed)19.9(uc)26(at)20.5(i)12.6(o)0(n)-530.9(i)12.6(n)-543(c)14(on)24.1(ju)18.6(nc)26(t)12.6(i)12.6(o)0(n)-530.9(w)0(i)23.1(t)0(h)-530.3(p)0(r)21.8(i)12.6(m)12.5(a)0(r)17.6(y)-543(c)14(a)14(r)0(e)]TJ 27.0074 33.7593 TD [(im)19(pr)27.9(ov)24.1(e)-254.4(g)0(l)24.7(y)0(c)26(e)0(m)20.3(i)12.6(c)-254.4(c)14(on)24.1(t)12.6(r)0(o)21.8(l)-249.6(i)12.6(n)-250.2(Hi)23.1(sp)18.9(a)14(n)0(i)24.7(c)-254.4(pa)26(t)12.6(i)12.6(e)0(n)19.9(t)12.6(s)12.9(?)-254.4(A)-251.8(s)12.9(ys)25(t)12.6(e)0(m)20.3(a)14(t)12.6(i)0(c)]TJ 0 -1.1223 TD -.0229 Tc [(r)-22.9(e)-5.3(v)-22.9(i)1.8(e)-8.9(w)-347.9(a)-8.9(n)-22.9(d)-334.2(m)-10.4(e)-8.9(t)-22.9(a-)-22.9(an)-22.9(al)-10.3(y)-22.9(s)2.1(i)-10.3(s)-10(.)-346.2(D)-22.9(ia)-22.9(be)-8.9(t)-10.3(e)-22.9(s)-337.6(E)-6.6(d)-22.9(u)1.2(c)-344.4(2)-22.9(01)-22.9(5;)-22.9(4)-4.3(1)-22.9(:4)-22.9(72)-22.9(4)-22.9(84)-22.9(.)]TJ -1.7505 -1.1284 TD -.0193 Tc [(1)-19.3(2)-19.3(.)-519.8(Chrvala)-255.4(C).2(A,)-257.2(Sherr)-259.6(D)3.4(,)-257.2(L)-3(ipman)-257.3(R).2(D.)-251.1(Diabetes)-256.4(self-ma)-5.4(n)5(agement)]TJ 1.7505 -1.1223 TD -.0184 Tc [(ed)5.9(ucation)-347.9(f)3.5(or)-344.1(adult)6.4(s)-347(with)-347.9(t)6.4(ype)-346(2)-347.9(d)-.2(iab)5.9(e)-4.4(t)6.4(e)-4.4(s)-347(m).2(ell)6.4(itus:)-347.3(a)-346(s).6(yst)6.4(e)-4.4(m)6.3(-)]TJ 0 -1.1283 TD -.0189 Tc [(at)5.9(ic)-419.7(rev)5.4(i)-.2(ew)-423.2(o)5.4(f)-423.9(t)5.9(h)-.7(e)-419.7(e)1.2(ffect)-421(on)-415.5(gly)5.4(c)-4.9(emi)5.9(c)-419.7(control.)-415.4(Patient)-421(Educ)]TJ 0 -1.1223 TD -.0183 Tc [(Couns)-328.6(20)6(16;9)6(9)-.1(:92)6(69)6(43.)]TJ -1.7505 -1.1284 TD 0 Tc [(13.)-500.5(Gatlin)-425.8(TK,)-418.6(Seraca)-428.5(R,)-419.8(Johnson)-420.1(M.)-420.3(Systematic)-422.6(review)-421.2(of)]TJ 1.7505 -1.1223 TD [(peer)-261.4(education)-262.8(intervention)-260.3(programmes)-256.7(among)-260.7(individuals)]TJ 0 -1.1284 TD [(with)-336.5(type)-333.6(2)-335.6(diabetes.)-335.1(J)-334.7(Clin)-333.6(Nurs)-332.9(2017;26:42124222.)]TJ -1.7505 -1.1223 TD [(14.)-500.5(Mahmud)-418.7(A,)-410.4(Timbie)-420.1(JW,)-412.5(Malsberger)-419.1(R,)-413.6(et)-412.6(al.)-418.7(Examining)]TJ 1.7505 -1.1284 TD [(differential)-525.3(performance)-525.1(of)-514.9(3)-518.6(medical)-524.4(home)-516.7(recognition)]TJ 0 -1.1223 TD [(programs.)-338.1(Am)-336.9(J)-328.6(Manag)-337.8(Care)-333.3(2018;24:334340.)]TJ -1.7505 -1.1284 TD [(15.)-500.5(Zimmerman)-451.2(GL,)-443(Olsen)-444.2(CG,)-445.9(Bosworth)-447.5(MF.)-441.7(A)-447(stages)-442.4(of)]TJ 1.7505 -1.1284 TD [(change)-302.6(approach)-302.8(to)-304.7(helping)-296.8(patients)-305.8(change)-300.2(behavior.)-304.2(Am)]TJ 0 -1.1223 TD [(Fam)-336.5(Physician)-333.8(2000;61:14091416.)]TJ -1.7505 -1.1284 TD [(16.)-500.5(Gabarron)-406.1(E,)-404.7(Arsand)-404.5(E,)-398.6(Wynn)-401.4(R.)-407.5(Social)-401.4(media)-404.6(use)-400.2(in)-402.3(in-)]TJ 1.7505 -1.1223 TD [(terventions)-717.2(for)-706.5(diabetes:)-712.7(rapid)-714.2(evidence-based)-717.4(review.)]TJ 0 -1.1284 TD [(J)-334.7(Med)-333.3(Internet)-336.3(Res)-337.9(2018;20:e10303.)]TJ -1.7505 -1.1223 TD [(17.)-500.5(Gabarron)-308.6(E,)-301(Bradway)-310.9(M,)-298.3(Fernandez-Luque)-313.2(L,)-301(et)-302.8(al.)-302.9(Social)]TJ 1.7505 -1.1284 TD [(media)-252.1(for)-249(health)-252.1(promotion)-246(in)-249.8(diabetes:)-255.3(study)-249.3(protocol)-250.5(for)-249(a)]TJ 0 -1.1223 TD [(participatory)-791.5(public)-790.7(health)-788.8(intervention)-790.9(design.)-784.4(BMC)]TJ 0 -1.1284 TD [(Health)-339.1(Serv)-333.3(Res)-337.9(2018;18:414.)]TJ 9.843 0 0 9.843 441.014 476.107 Tm [(Address)-337.6(correspondence)-337.8(to:)]TJ /F9 1 Tf -1.4572 -1.1116 TD [(Leslie)-337.1(E.)-334(Kolb,)-337.3(RN,)-330.4(BSN,)-337.3(MBA)]TJ -5.6157 -1.1174 TD [(American)-335.7(Association)-337(of)-336.4(Diabetes)-340.4(Educators)]TJ 3.6459 -1.1116 TD [(200)-337.4(West)-334.9(Madison)-331.3(Street,)-340.7(Suite)-335.2(800)]TJ 7.0211 -1.1116 TD [(Chicago,)-336(IL)-336.1(60606)]TJ -3.3349 -2.1253 TD (E-mail:)Tj /F4 1 Tf 3.3982 0 TD (lkolb@aadenet.org)Tj /F3 1 Tf 8.9663 0 0 8.9663 62.022 749.6502 Tm (528)Tj 47.6052 0 TD [(BLUML)-334.7(ET)-338.7(AL.)]TJ ET endstream endobj 65 0 obj <>stream 8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0 b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup` E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn 6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O( l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~> endstream endobj 66 0 obj <>stream hdWyXSg9[ 9q׺WV"*"kHKv! D MA\p֥vu: gvy9~ر%`іYHjf46#051fpM֡2 (l_:HqjrT >jhՋ5w- qibD-JD[22DQp$Q,O1D(U"Iű tQv(05+[Z(ڲS,[,JI$ D_<Ǜ{͓ooxoғ*ċVm|k){ߙ6e͔)l a "-fk[јP$tR`ԁ@~"4 ySNwm߅, 4]jc'ULZ D]anu&|rm0ΐ"zMCB6 :|H YwcX},{xjdVN z0Lr:>Wf`P B-a&3SpD}$0ۏh?~IQl(s$ZIY=]hTK.lyRp<= xVuYFRYwy:lJ1+HBFuYҠm *@Q. EQ0o`7;3)ꉨ!AC7a_AQ0ێl33F]48\a,OJnX&a^bi>=/( B$^G{c±ԸNI%xc ߆wĂbQ(S]ki JMZiTb Ba4OVehu}P̶G 쭔Z0?{*RN| 90XW~…(cfNZeVԚ(͈29~ve;GB3X P7ʫRZkY4}0e^[z o?8}EҰ4tK?56/ǿSQq{̑gOSSriihSWxt ZXLO7t` PA2M[sp +ʙRMU6 VNo=XrP{P_Vfcʲ2Aۻo>]hQX_^s#w4)UKN;`f+LǑ|FX$ P&6auYxg2 FM?o5~zI_Ckr0)VWs5vS#ݑ[*gLFtQ7kx=xȋKAÕ[NO[SKKrdz=.# B*Ԫvg/$؇v KN(TiLVP\fׄ!XR麣l]_>i1蚹Q#W"6S~\icHV7qhӵZ( Z;_ 5d%`%D*2Q!g4Z9{VEK323vaPa;+bP\"_d/pu䡠@2RWs霺÷.1Ծ,y1VWZ깯ќ]L,Ve\TEb];sS1:MHSRw|#dbTo49X 7pL24wYFg[>uE= lǙG%3F9уu+`;Μl%Edg h>Pr4GPSr-o ;?c3@oWǀhsSG_fjBN*SеѫO*e1nLIt9S27pǿ0=$m?vDBZWGEug?\;qy٦* 2g?`'ĵBpOF׎;>x 8:phGdx0[/1x} M^P,qx0u8{W/C*f|"/6]9(!hiO<;`a>-ڳ$;Ʋ0,!z컕Tթ.!4T߄ L ӥ>q4]41  h-:eaJZZĭC#̣mA,cǙkߵ;$}~^`+ [#TF+Ud&(NSF_|uFVfj=̮-S j>;%2:MPgkujޤ PaPY]-N cU(9SW^FUv8%;%))6ԝp%b "K \ȌuܷO98\w t)yYӇU'^>GS![IJk BsȨ;ا[]'UfcȾ:6Zi*745rǤ3MTC5 tz49x//3ׯU_^^#T%[9^k BqZVue2rB;dЋm 3)D]l@LvV{agQ_F& Q#۽8 endstream endobj 68 0 obj <>stream hބT{PU{֠ tH0""Z,쪫.n:AMGMs?ι߽*A#T[$-5$Lyqq_Trd=FcWGwMZ:'TMqͲv]twN Ʞq;. "$ɚmҝBs]Jϱ 6c4K Dd36M0:̅dKFf4 ulɷ: ̒~ɘomI%׾1n1Y6>/ JY]0K"a ,%>B $ 22A0 h*+l"TT?$xSaXuGs&Oь(R@9]N6 .`{^9f`*Nz>JD hhQ\5Ch6;)]#t| [6~%V=09=MǮ( #MKc:F0p"?qx↹ WPA!bH3!ůP%s!J<_,`%!; }A{}x3>*X6 2—>OiUo25uiA.6pq7qȂmay.ZUQN q,K8 yt5ynRroeβJ Cj Y%|@/rKtx{NսV ޝ :߄q6w14@Y8Fb~<!5+nPkb;nTtFX?cbP.G߂S޾M ^?Z995,Lu%\DSe? ^΄/~ydO} ?ѿs/`4]-hA=6^QHnFRZ: c+ a z`ܤp&ruy̡ nB~ߣL}ZUu%1|Jzݽ̸bÊsN -5Eff˜'Y~Yධh?Gǡʋό3 ^Y(A Aʁ=c Ø8{A~ B}|1/^G%[ċ0 ne@1$[P{x+ǥcez< k/oeDo W f. [g N 'ų=_v4L۶WXGC8.zSIv^ױߦ%eFedOVTڂ7Aa/uD5'5vռiaXgy̧m0S\IŤ{\Z%Vν\\ѝ3=&%)EE+Q45~Ld]\9򝶮chQ`+b9͔ zat5o7ǐuv1 ka-EW&6DQ[9wp endstream endobj 70 0 obj <>stream 8;Z\7!=m!i#iu"-oK,_"W)Z[0!aS_X=hCB!GDLE:Bk%PX.]8&)#]*5S_JAU--XGqMA\]0@/Y%7MTT.^m2>A0sooIW8TLO@s>;!HS]2 ?"/jhU#\-u7]2)57[JZr@cK"\%>MEG9>t]P+gF@pdg7="b5E0>YAfO)/pc%F4l[iU kC^_\RtWU2QV%kqd'@8Es5@B7aZR[9AE)fAp'f-gZhTR0;#CLt:R"#"~> endstream endobj 27 0 obj <>stream 8;Z\7>7uQ2%-7C(h!9&C6T+NqKCkm*B#&&6S#+9&nt=%h/T%@b-ZO_!5er@D2+&2#ZOmRM7F?:;]7L'rGfp']

j$*EN6eKk(8AWc]T.tjJT,%V$_.PtbG;:^@TlhZKO8T<0A$*D3bg:T6:**VWjL+LRf;T< a?#o&>k endstream endobj 39 0 obj <>stream 8;Z\6M\:Xb%-.A;OPeaYS:d-)V7!86R6*R'+c2$+qB1Af6Ba='X'('LlfT0_`F_DY1r"@p=EWD Z[]q=X,gKmT0KMs*adQgIXYV&A:?iigG:&eFjUHj4]bo.?Zn@6,Xj]`h+;Y+@W AE@*%X0m9h*/_HL`E52.X$)cA8#WI6l7+a;raLrTN=^2oV?pO-*7`#-ScncD,EIlO WCt(&2g\/<8/GtJl,n\HdC\j)O8aRbe+?66\p._gjGN2GK-PUM!2`CP*W~> endstream endobj 43 0 obj <>stream 8;Z\7gD7XK%-.A;OPfTEj)!5>Y#u[WC[0$,Xn$"mL]b9X`f'R B.s`>O;FC#lpu'#432lGa-4$Yji4jt_)`B0]I>N0KenfRoJiI/6s5aib.Aq%[X;5B3l0U ,JDqTi_Rem^s$M)@35$ok]Ue.SDQ*#Kk>LuFj,\^eSbXn/UM@,0_F_EY=FB)eo2e+ S`j(7FJ?t_e:mCJKN`Qllk>bPbI1nba6c5Z/MsfoXJ8SIi69 endstream endobj 47 0 obj <>stream 8;Z\78!:e5%-7F1j?$RWZU-'kADuM*^?cE.e)E'hIYaY]d$JXG]@ht_DF(34TU=C" 8l`9I0k2aShAOKbmu\mL`-O[QfX(`Jr9"Cn40k[%FRX:"`WF%9LJG'%=9U/-Qb^"F RnPGSC%hoXK"/`ToE<*g*Kj*+6c$Lhs"T]fe#UX<.:(ImA)Dss6: Bbt<5bL:=(YPT^WIelC6e1*hkYeg&r"QFH!V?K@u_m9]tfsWo+nTnYB9s3lSE;@Z; ZJtbcG*1g@UCcn97*=dHeh(0CB?n`b.E(*UD7/7 7oeNCddE.$]@=RY)CULgo'=^T#j0LjEV(#[mM5n9XM0X@'(9,OGcIr@S=8tI?^Wl2 j%k'ID.TG(K?QefYG]A>MCPVEX6]q"n+="[DnZn>+$N*^2ZQ@'>?V~> endstream endobj 51 0 obj <>stream 8;Z\6;&7%l#j_FBaE@4(m6+<;7'Uo>q:Spp,\`0o4>@BP$!_flbILGq%#NgBG9Ds5 5u7(^@Yk:;&fS=*F7c!,GT"]J,*Q)n/]CLsh5rP8f*7OCWFF@dN@ZN1[F-dW=l8Gk k[G]p"QWeDY9AlM=Go"^1DY@.5\#`7c&0hWApuJ;jg(^>d4_rbgFFga$u+b\K@,QQ b`kZ!(A-n03cAUe`dRgGh.hq?]U\FRL6\_]Vq%2mK_K9[TOhgo%QiTZ%0X%>/bMNg 0ob4AkBLQQA-4<5"h3UT1WS[DkniBf9-_E-)8G.^Y$emd7'"1>NXkWcG!^-=\A1kj L=k1ErBC5!hc7F#QX+dlZ*=X[p# D`T4iM>C.`_"4"WTPNN8kuZ4WkPD"q^q>QXB_hmHF,^DY'WB,q_rDK`B[rCB- endstream endobj 59 0 obj <>stream 8;Z]!5o.(fp/WLrZp1 1%dl2'l]f#9Dm"*Ak9f9=OT--CCI4Qe^'\e,RmuXA%uu$'2F"@i=P:43Jt7Gg^BC6 ]mfchl$%n?Yr[R((Q*iK$`u<*2P(u==%?g1(P\$C4>dlG@_n-(4sl9Frp\J4eVpYD ..u6AV-:iE[pjZW^'.[2>+qLRLZPlB@koP2pdpc*9F)ep&4-XGK`!d4! endstream endobj 74 0 obj <> endobj 97 0 obj <>stream hbd`ab`ddpr pvL) I{X/?x!Xdll>stream hTP;o @rQ7tJU)Cj9pRCISulvyc:C84 G>:Ud9Թ'rᾺJɺN37N"T %oUxQ϶?s}78D%$3_m_X\$K=4ek`Q6ܸ< o}d QZ9z+?#+}vg endstream endobj 75 0 obj <>stream H|VRF}+8JA3*X $.%lQtb?6ߒiIQeϭO>mٵD|:̢d:2V4IlObƏדGv eijdR^z]kheu۶ٜ䊝7/ȋ`[''Fh!Hrr |sx$;ݮ`vv-)h𧥐 mUdD+L]eT-7eXWB)!PYAn$de5)38LOH#[WeȀh®D0g[_t6^HpW(S 2l2OT9(b6CVa,pzh*TB~*<3R ^@e}8WH1WmR tHf- )SMT̝Dz !M!؜Ŋͺ)KYȲί=5`Bujb9 ص/|m \P |]:&Lή|\@r%T ߬z ԡ0dz$UeHB)DʚylJaCJQ*}8Ҥ*X C=;p4CV `MC0ƆI 3>F XZ /b)|B w 0ՁE 36(Ю=#vbt̎<\Lwm,$ }<*6{x9;]-׊SB'n$x,ᢥ=߆ld, g~vWN鐰=$ٰ'5ѲҲ-ܳ3;C%!ոĆձ$վٳ,&?>stream HlUn0+|$XEԱ@ zoE,b|Kg""gޛ)^]{]^QաxeҮ]b6fO#g ^}8ˉ>Lӳ.{W#ٕvo3L\Zh 8~#9 SݲGm yF$%5F  ~qd[p\:E%`$z>stream HtVMo@W[  9RUVɷ* 8 at>70ޛʳ>վ=6u.<úsLi]D[fCFL8B.@͐[wx1+(#Z9f`QzF.L̀љjRbln!9B`>}WZ 2(tٔZko$E{7҇/ab)cN/y.v(w# =HhŇ +"DeO )h̘ ڝmc^d 81uzg568R=.-EFsG!Bii?07dK[b~ipb[+&+Uϛ6G2˄DG/Z3~`}BT xZټC'V#\bʆuV'fh0|].!iGU%Ν/.(Ўb~g=v>-jkF1ߕ#[W0T*Bnmݾ&4B &!w b'8{2qhTy;ʙ2H ^N}Jhͬjb߼3^w!cdľ`y q M އ@W-x9Ă Gυ'Wg1:-'"R! '⥼7ZB!Xçr|J%6Gnl~7;"yL"[CV˽E\ܗ-_S%g-wv%ӧ~^6laJ7\xbо>`I endstream endobj 78 0 obj <>stream HlUv6+z)r܌`v'rһYȴܐڎ6ߒ[*ўvfnUݺ*>]}x(6j{NUJ__i?Lv&c,)6L>}d fb>0-ϫ^T ?niwx{?{ ?OkMs7ﺥaB~S0Ώз5CKbDD$_w1JeerwG zOr ><&L0 Bn#mj$2 (jf#׈TaڢLkUc/^UZfWJmFy<#Lz B8ZdmͬgI=KV Tk߷T][7_(xH5Vn [ZZQݲ6@bx giÂ9efHH@diE{~aѺ6)|R'~vM*FA7DЗrc+Z,ktX~QD̓dhD&ʠ> \ؕ@%Ie jWe;BG΀>ݪʀ{9Ӛ zUhrk)nD/ E1Q9踄p:hS'$D 0 %~Oԕ2v<{ֲR~3,5 !ERXdJ5( mg* r((!Nk8J^-ՈX!}ːWmJ>UȮD~'Δ:, h:HKNY[^z{Ciȓ Z(D5ڠ #]H?ƎISLY/|`ivK)Úc ݹ1^ ?[<7iPu6CD_ 9NelD<{~2]čliq5kY-.XNIcg- zLfË)Fy~'@+ endstream endobj 79 0 obj <>stream HlVnH+xl#ͥIޝX$nɜpD*~^--Jv U>&VE|a.KY]g3sН ,M\fmc-c[ YfǶN RCZҖfe-MdP=~ebaƊq>h+hٲ2L93Ƭ5-QFA/nR%f(Nx5wE-o1G2VG/GiBE=y)Kx9JRܜ@޶BɅ9G \oµ$yu_w΢,-u!5XmUKYh?KmEn#O3؞dȖ !j4P]DFk}P7̀_c Fw o(&Zz5hN:8SȢĨYE͠QZ3ǁ|–`ƺ{pwab2Gz-$ .U,@X2XUY;[DYS%M:<.lZ!"a,l RTUC?̣ۆV"MmJFytO YwԀUr{F#OϘA=5UzR8ݿwˎE#>]ᓰkʹ3ܨ+)ⱫVh;)`|>stream H|VKO0WH;gX !i+qmGƩ?eP q؞fGX=,eu\-xtQERMAT,F&SIXlHgqVQcRRPUb6ychG1{-OjG/T3gŜp<א ^VHl'JB:7Ql/\}(HD߸rTJ#COΑTsCCGZ%ǨȵS08߽Cڡr?g4\+/U{0!2*-S+vYqҔU[ʢ՟K*˪,e>shZJT}RgBɖy Z4V_و~|wb޳(\y #l'R U!Ccnҹ Tl,Hھ,Viy:.6R|!Q *H/5qcྪ chBuA%'- #նTL\aSq3T̩fU&J(s~^(Jܠ7 Az8x,.2q@-J;_qJr"G o9t'ڪguD?Fė7\\C=lvY L%0ed >j>stream HUrF +xlF^VN^ɸ$QSshm=\d6e)_K'ݢTN  :Z}e29m"yZ23$B5-}9Y‰Qã3_aK3T1fnL` z&صdGObnR Q2p6M U$!y*xo.@ O.J#D*DKT׉Ҍ :d~%Q?'+p㦌j1É ULQ3*BdɁ5A*؏3 !Yec ܴvqF̑Gۚv:;4T&dvY0hEYB?;_G aí/RYU%(+{.-G)P Ul1㽙o/;=n _3GD]41GsP)KFAP ]t1v~cu 일L%MҒUc3':k0ui>FTQ_spT}+Zd'x&!lm~B)]߫Iq}ʂpn{+vCKӓq!1,}9l:v~ <yA=EŚ PqZ xy;KT {Κ8%Q6 AK;pzZߒüS2t20ΗH4SB"t ex# endstream endobj 82 0 obj <>stream HDRMs0+8-M2A5# mvzE?Fk29e d֛z&YCQ }niNKq\TgrM6WX+`{ػ8?ӯ<T b5C\䌊Xw8 _~Sm=f QW6 n뙈mrj>stream hdV PTg~3gtw{ <@@b"91F]0ED׃xLTd Dnj4fݘ~Ij~O(L&s3+":ltiEĈ Ino`g P>̭ﮁ\&+fȳ&'&e#FI_=qOzS 1YbL^V9-K`fXli(sĹ,u00g'',(f[&sњ"ZtKv^Y .Mc-V1ʉJ6%1a2fa˘Na|8'&TL0chd\Lsy,+(;,/"/7ɿSS2 N=Q,Eua/$j%Q*g)-ʟU}2}|8<.pP ,Ou :)R3m[ͼEq8xcPaFx|R{VͿ߹j x s 89Ր -ǛtA 1>쿭0ڬ?< t̺/QllR:p{yp!UE(9v&#CQ.-!9I8pA-AJ4@_,k`܁3Żk" SMsgN=n H}+I 泠 ~FyZ*pkcSI ؑyр!>yc_F^AI3W %w#m~K#ȍ^dbGׅNZ H:DE4\|J emUj8$pQj67K,VBL37N?_jy6!z.ͬYr#3'Qkƾ 6y-B#Mmgk|^]+a$;iɂxCnς/Yg\ c,FuA \&uPwl߅˚/ok*l/4y7'1…,C1%T@+ 5E]-`k-^+E#3Gk*L¾zucOXigg[] B-wmsRRp'(< ;pdv&EbXy ZAǼ8kVDp܁h3`8.a!=:<>y5v|| dU0\Yn]:Ĕw ߡ6gD8нݵk _MqF-Aw yau{{ybrkS=¼v2r wJ'k7\~P;kW.Sڣ}C|I0PWz>tz@,#CE@gf&/ CZ:;*"* endstream endobj 96 0 obj <>stream htW TWfPcPTa⮌Q]qAQDEihvhzg_f_eQp7}K11'-sj?stU޽fcemmyO+d£c=ƒ'H-XkݷxM@h[.kuIظ09sYLu뫋2ieP`ɉD' q NN+-N 2HpSxS4!0(8:0!)6#<&VrS`LМpĤ}A +kg5ʊ5ڊrrrZXEXyg=вޙس'_ϙp0,.0*ˈƙA#a/KԱԧXX76ٱ;:8Yv±5鏰ɬ9k0;uε=}Y\%rL'*flg p]tdB1 &3ZEf75HhN(ӓFk,ﾄ8 F8wэOE6~{L1GEpAC=Q uN~fJK_n0V'`8&oQVʄDhB89PCcbI"/WOoX yRn) b3 j;5:^ze`6簓?|NPşI= ݽ qqIoʌ:Oricˀ:U&mY]KpJQ+g‡%":jfmL\?]=_=;oTeH|'\üוH]ρp՚ q{]2x 5ڍ]ʄoa)KNٳ3Dz8MAGlS)bc([fVlH *u$6:&RV91oee\8$(:AJ>dw+%CBN3f8PqX &k:Z4~$,bpVLܡ~8`u @@(DE(s":vϳ^`# 6vXof{0K ЇZВXz\nWT>(! xvs7Kkᔙ\O,{dxT| SOM č:S=cB1LY |i\pؘhyZQjU2Yޔ϶lHE' ڬccP{8vHNP.ʺ 2n1j}+IQLRfe\4S`n,2|,dEѴ 355Dr9yJG1zJ:FT $ ?Xi~KEM{\(z"0a ڃ;= m'?8g/_+1n3ڊS% 7 J}>t ѬidRw:wpY8&aYk?S8g" 寋Bgz޻}ס3v`U8%;d$rG` [YyG뜓Uu-lT3OXԂt7ltsMN5e|v3 |=d'|H _mg` jj8l;JVJcwma݊W½# rNJc(QOʪXx?ja:stǩsH酆 F(9GMk2d,#>!pHu}lsC*rJ:"㔅cK '(׬$nWwRq'xlq9@i*E+nz:–'MK^O& hLç2τ;Vدa:tbuJAIS@*_J 6]y_ ZKǩ<;R2m{L++އoxµ~hꋎCg KfcԤwDqU MCY<׍O>91o^ҡ9A Q'/ \W l+}pzי+KED8l&R8DyC=-b۵,P9Q5X(f.[_l9_v8Cgs+چʶ=-[ql]"?䲔lwJ5Gi $uk:qYoUv'ջI =_V!\ni>A.R%2޴?$]>Gzu\睗hS挖t7l>_ Z:rH:CS{V(+ SsO5;K :8z_ΰ7 0XxwÿxVen2Q~‡ Q}6|}zerR$3D-PVP'QA++FʬQA-Mۤ. rcdO{}}[kRCt"R܂E뽓 8Ґ@ x!R|$MBMVl&򀎈'1.nz)ٹLz*+ D郊},Bjϲ&ܛFdfd*Bza>ߑ#RܕlDznʱQ˨б)ܴdzے=ֱП堛*H٥ؕBKpK|E{*wY 3Q>NC;jK5y +C,A4 2L $S0ڭ%38,{;F#7da-~ɳxzh3oIO|6'%ўޛ/sWr)V\*5 mEr\Xw:tԱ<ޚږ%rk|7H;5uFsS灺nxsјL{-J]ou:#2|27;%v;}֕C.#ɵigg3TSI*X]}Σ">i=lre68Etma.Cd*;ȩ}O <ȥIR$B)zZBR3AEfepIqiѬ{eQ- RIj rG.^=Pux(&kd>[ʄd(%T%y ШL諠j5yQѸ.J_ַ05^*2X RA5*kn&,+aښ "է,=\wqN7P`pjR9D ٢a5faF}n [RPv~4*,+v}ߥ  FeY&*E )UR~ThBgUiȘ̼m>a5bTB۷[$DT ,ɴ5jXWT=фDP*ȃ,9-PVU2-ݺ/T7++D1jpIݏpQ5ql:8/!c׀9͋ U-`bij^9i Rqo5r\3gx3jSD~"M!# +&# 1-@cH=ɯju1}eP`0b'NkC5^+ endstream endobj 100 0 obj <>stream hlV{TSWs6R[{(QDjkEPDT@ /@B' ` >Z*:Tth:X3UG;N|ZwǮ;N׷o~㷿}D"???6!en e9o(Tg=?ϳsq4GeT?'۞ϯc0^^QaJWD^[#Q5ei\iF)TJ+,UNr4@CPJr9R򕄒ʔ,JS8 Je*MQ4n4`KrTF)KVʲeY Yr/d"#&#EE0(\$Z Z'66ґ(TD(BQ_)H"0&'OJ@]z7}(@=T4Ygfssg̑_\"(YTvnm;> Ύ5׆ڒU8NnX=ێ MHvkj}AYYÐ[)uD&¦l.s"@g#Ͽ))+z-=̊wIƋH<(dw͞Ch53 6 5jINTF{]-n4̢_Fw\N [A`=ܪXo*J0h#M.E/p'\TK8޶ã4_21VtGj,9-l:m}+?|D#{$`*k%"Z<"`$߁f^ s } fPG Cb9xGvѓpWB9=ZmJm'Y#O5sԡFv%X __8 b)G8s0jzC~a1-1m4n}dy!س1Ӱֻ!ֳ2o vNXDn w PɑߑmJyNE'\8`rH V?(0U}%!L'41sĨP¿ 9b[) CCX y/Cц{#y\KnZ(cIٰoK2 l?,{uMz]Ur⯾b6)vm+i7 )-вNM_8!m߻-RhwN2V؅cVlm7=0W ɫ{E4}E{3Rt_HLt n5+e;]NI2Ծ84>B Rٔw-]gSvz6rK}dz>Zz)3Bj'ijSnfN$[+r]@&Go4thk\{8s@C'ޡ^Cʍj\8F!݄b'"Ó 7٫뵲BWFMNvm2X !4S$hHYݝօ8\5]mY-X h-yu<$g pdҨe|^TE_:.-D54XհkC03LmLbOӏ0#: endstream endobj 101 0 obj <>stream htV TgQqi<@-2"DpFtؐCIIF5Q94x`hEш \$1!A1R=!o!/}꯾Q0JFP<4%.9+*$yB\n& yuXۛM,\uAj7A)\\jϛg֎ Ak} ir FmJiٸH_ShZ\hқZm…EZh*ƅ%Fs~^_k&}q޴@[8W_Ph.]lFԷP7|30j0GɌwdB&ډdRLP%1ZƗ a0+-LbbbCCÇ7zs;.sK2b&WWy3G#9-C+3HG?ZWJytXm}c.5x¬\\qCd!)$Rʐ,w`[y ~79 1T.n}ٛG_|Yp co*XJɏy8acHmp[9{@3ƒkӣuI{G`!F;H甘I*y\w;*t4_Ux)[s㻎K6nmp|1X,Z*ؖb̩D܋gSݠ88{F|Ш_ (?>pS79!7^TJ?< ;hejWGޘ.9Boٿ}Tڷ}O4T7:L4'Ҫ6>!Ov4u=3uNBFFͰoj.Y^BRy$XY 7[<4d)joA[@:wޓcqa(T)E5r_d IlnmqBa>ޗ9d ><Sf8ާe 61&]aW1\Gߝ×J~&TAmq}nag0Rn&*QhP[ (r8X ]r8fyxESA nredEWsA ʷX.*bAa5dCyA@DtM.j{E `=46vL'`u!@7.yx g`%]:pminypJtL|*zY3 ёU.siSh/5D q}K?7Ω-~?׉* :Pmu;') u{(g+PNmO{\&s-{J7,8;( A>B^Ek69]T|P!\3JRҪ&cj DVf^)AG !0='SvѺكꘀ^< 8o&7ge' 83PmmRIJ$ op$艮 \~Xi'a0O@i*9w3Y_BLgODnݼSrrgKN$ֻ|9U hl=fժMmn[K,%N9 %Rsڊb.U] 1Ҿ+@r f<} 4({|hataڜZ߸_+⏝t6\:'Y@BmDϚe{'O7nψa'΁ޔyy7]| _,-/X3QF?cvԉJZ6B"0,Qwm■m To׿%'٦PSAhX_rI^TP".m+ה 񙆤y3 6EZ "N=O,6}Kyu)[vػXYKT uQTlYֆX:Mz6}q[g?ڊⵅ\$޷r]"E{;D 9sCޭT/IQVRlu,":˞ +ѷlhѯ\)[[&q5˫`7TA^t"/B%t#D>.wVu endstream endobj 102 0 obj <>stream hތUkTT>w{{έ(y(Q(uHhlFTʲU#b$F#2a hDD" hjY"H@#33k:g?oCP2핤ՆDs$m 3x G{t(| 6|{OGBɃxELQğ"$((DdIU %a ! ]RS9_jb"FQhP{qU4)S*;}I6&`5#!t>fQq^1ds?bb5pX)DOc}lcMqp sV xi륙eF}cssI=X&-C)bJ8Um@F]0oW̄W[_70- =AP6E{wyz$ѿ墦۠oa,o1X0 64vsh*a< YvtIڍ&2)%D03?B: (tp0%Xw3NG|Lff8k\fFsI}?N7cXd7LϵoJSkN`'zedHp)ɰepv;Y/vtYr'Yq) >'h):iWrbK!wVx:%y>{\^={a^R[ޡ]*Ò?`! a^ ,=& ?pdaVwvjoǗ$o رۑm սqHP:՝J P.W 9}~L ])b\[7G<C̓-4q 6ǶTH7P<%.^(aUkCvJD}rC{J/*.Wa1=Mzm;]͕[Z,UGʎ VIڢw۵ŒOtHCM%3Z}aayCZwKݥyJPˁPݭC~|Y!@@:u|$WZUMw7  a!qk& Κ\VH}RCHL~-j M *ǰ~}w$kxlb42l ]YP'`PzcF5Āﵡ y(8Y8(% 6׿Jt!alB z1Zvn3/aEΖ|lrKҙ ~c{ӹGɑnۈsk*1=XSSV#Li!X%G1Oȵ=qZlih=`;(=24c{ [˻~"SWHpzȺ~6 ?r?!4>stream hdPkPgESf\ g?őTgxPyF, f7`HB$*41  ֖d:RCivi ~hǹsű yYT |m&9A2ܿ=<T7hys><㽞zWUk]lbrk1A| &19MSi9^r"{B#kSűlZM [  6p'*YTqJAj*NslZ&Sk̉rWJĸɰX v+ƎaX(F`X#߇į[!!oK!Qz*宔(c).]pNUƐA"5:IT60`M;;7dz }O6 =nDNƒ~/boF~2A g}*LZhgP-{=)CV6y=+4^BMV%%HO|Fح[H-fWg ObP:y?Fė0t>V8 ܻ;!OCLR\r_<'LohWM#HiQbtw,rpH[ZoJ!"!EYX[+ z XR8B{mc+( r~pyz _E*0Ja qbY0piU_ FEQB9DgVF6;tDl7Keo)QtmCU &n JJGg,n,?Cjծcwr_I!(|hUӺbt} cVBv>;A"ᱜ58 ~>D}@P!qʗ[OEz@¢!-J.H!̀}'\kEsܦ;ZM3p?J6_?z-^vV4߆p4/N q!vmM-_=p-AEnϡ`F% endstream endobj 104 0 obj <> endobj 9 0 obj <>stream xZms6+΍Hdnlg;mz|%b+ I;q=$\"+Iƙ X0O1O_B9 EXLH} d %pe$<xLXǠxLF16W B tRy>^R*\%P0'8S>fVSX謧 JOFcJzcTcKQH |Jz ] CRq1DXxYW<(Qƒ"qF 8FDpb} x%"w"I/?.|6~ ~ 3yQ,. XHzY}G!^NJ'.aQФW4IXhY&:k J(-*"Tz) JIt>u:Klp9ޕUO-q 8:4NQNHB k; ?z0e * d8 IPzX!FD Coe"rp;~ j8fᑿ|(tV㤙CHzV]E28 3. Alw-w(D1sDEhb`zne4bO3aќE7Ī])pճׯOO;(X\m6w &_6_3Xvpkأ%b}=fre:Vm٠!@2 Gl zUeq gbpZV4̧lW={njKt͌8. 2@I[F,򛂐mcK†U9"Uj}oo̾ڑB[,ekY٩#Jfr!bLn]#|n.?Z- ی3$?4t)4{Ҟ~WyCO*k 5D&!ua]E[al\Tנ7 BXm\*5Ä!s6AtaHgm>G~k} jطV¶?1J,%p1'RAa`kyf ayggom\ YF4 c]`c쮳Xgv.R6܈e۪7߸:ZgpKĐ(xG@.z@kyЄ7->Os} :XS5pضIp^>v:oؠe,-H9}ف{56qglh6AvW'_{>ҭ@T;=okw&+{LvE6V34PiX445a,>MFtDF ;BW Egq\pF.JӁ++:zV)MA]]cn{$ RޡO"cmD6~%a/z?D E3TA1| 9t۪JD#S$_{@w ;gzw[ԩ!'I53Z8ut3t n]t5.prd@Kkh ":J7]@HdwRjUd36zGH1 2H_B! endstream endobj 105 0 obj <]/Root 74 0 R/Length 325/Size 106>>stream x-+Da1 ~lfIYYJi2IBh,%ʆPopx眾>UxDB"* 蛅I_W0w5F+J`rP´zgDU2Y|k1I?MIh+Pʔ~'9hPhHFii6FU_31Di N̦j҄4CyU~o<<ن1ӓtڴaM{h/SݺB[Ն?tmG/8|}.};>N6 endstream endobj startxref 125356 %%EOF